[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 261
1. Magrath I: Denis Burkitt and the African lymphoma. Ecancermedicalscience; 2009;3:159

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Denis Burkitt and the African lymphoma.
  • Burkitt lymphoma has provided a model for the understanding of the epidemiology, the molecular abnormalities that induce tumours, and the treatment of other lymphomas.
  • In addition, it is time to re-explore, with modern techniques, some of the questions that were raised some 50 years ago shortly after Burkitt's first description, as well as new questions that can be asked only in the light of modern understanding of the immune system and the molecular basis of tumor development.
  • The African lymphoma has taught us much, but there is a great deal still to be learned.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22276020.001).
  • [ISSN] 1754-6605
  • [Journal-full-title] Ecancermedicalscience
  • [ISO-abbreviation] Ecancermedicalscience
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3224008
  •  go-up   go-down


2. Omoti AE, Omoti CE, Momoh RO: Ophthalmic disorders in adult lymphoma patients in Africa. Middle East Afr J Ophthalmol; 2009 Oct;16(4):252-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ophthalmic disorders in adult lymphoma patients in Africa.
  • CONTEXT: Ocular manifestations of lymphoma are rare events.
  • Most reports of ocular involvement in lymphoma are case reports or reports of a few patients.
  • AIMS: To determine the ophthalmic disorders in adult, African, lymphoma patients.
  • SETTINGS AND DESIGN: A prospective study of ocular disorders in adult patients with lymphoma was conducted at the University of Benin Teaching Hospital, Benin City, Nigeria, between July 2004 and June 2007.
  • RESULTS: A total of 111 patients with hematological malignancies were seen over a period of three years of which 62 (55.85%) had lymphomas.
  • Of these, 51(82.3%) were non-Hodgkin's lymphoma and 11(17.7%) were Hodgkin's lymphoma.
  • Ocular disorders occurred in 16 patients (31.4%) with non-Hodgkin's lymphoma and none of the patients with Hodgkin's lymphoma (Mann-Whitney U-statistic is equal to 7.500, U' is equal to161.50, P< 0.0001).
  • The ocular disorders due to non-Hodgkin's lymphoma were seen as - proptosis in six patients (11.8%), retinopathies in three (5.9%), conjunctival infiltration in three (5.9%), optic atrophy in two (3.9%), keratoconjunctivitis in one (two per cent), desquamating nodular lid lesions in one (two per cent), papilloedema in one (two per cent), and upper lid mass in one (two per cent).
  • CONCLUSIONS: Ophthalmic disorders are relatively common in non-Hodgkin's lymphoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Hematol. 1997 Apr;74(4):163-8 [9174543.001]
  • [Cites] Ophthalmology. 1999 Jul;106(7):1339-44 [10406618.001]
  • [Cites] Ann Oncol. 2000;11 Suppl 1:3-10 [10707771.001]
  • [Cites] Surv Ophthalmol. 2001 May-Jun;45(6):463-71 [11425352.001]
  • [Cites] Ophthalmology. 2002 Sep;109(9):1717-22 [12208722.001]
  • [Cites] Curr Opin Ophthalmol. 2002 Dec;13(6):411-8 [12441846.001]
  • [Cites] Ann Afr Med. 2007 Sep;6(3):89-93 [18240494.001]
  • [Cites] Klin Monbl Augenheilkd. 2004 May;221(5):401-3 [15162291.001]
  • [Cites] Med J Malaysia. 2003 Oct;58(4):546-55 [15190631.001]
  • [Cites] Klin Oczna. 2004;106(6):783-7 [15787182.001]
  • [Cites] Clin Lab Haematol. 2005 Oct;27(5):302-6 [16178909.001]
  • [Cites] Can J Ophthalmol. 2005 Oct;40(5):623-6 [16391629.001]
  • [Cites] Ophthalmology. 2003 May;110(5):1057-60 [12750114.001]
  • (PMID = 20404992.001).
  • [ISSN] 0975-1599
  • [Journal-full-title] Middle East African journal of ophthalmology
  • [ISO-abbreviation] Middle East Afr J Ophthalmol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2855666
  • [Keywords] NOTNLM ; Lymphoma / Ophthalmic Disorders / Proptosis
  •  go-up   go-down


3. Futagbi G, Welbeck JE, Tetteh JK, Hviid L, Akanmori BD: Selective activation of TCR-gammadelta+ cells in endemic Burkitt's lymphoma. Malar J; 2007;6:69
Genetic Alliance. consumer health - Burkitt's Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Selective activation of TCR-gammadelta+ cells in endemic Burkitt's lymphoma.
  • BACKGROUND: The overlap in geographical distribution of Plasmodium falciparum malaria and endemic Burkitt's lymphoma (eBL)--an aggressive Epstein-Barr virus (EBV)-associated B-cell tumour occurring almost exclusively in the tropics--strongly suggests a link between the two diseases.
  • METHODS: Venous blood samples in heparin from 21 eBL patients (mean age: 7.0 years; range: 3-11 years), referred to the Burkitt's Tumour Centre at Korle-Bu Teaching Hospital, Accra and 15 healthy, age and sex matched children, were stained with fluorescein isothiocyanate (FITC)-, phycoerythrin (PE)-, R-phycoerythrin (RPE)- and RPE-Cy5-conjugated antibodies (CD3, CD4, CD8, CD25, CD69, CD95, HLA-DR, TCR-gammadelta, Vdelta1, Vdelta3, Vgamma9 and B-cells) and acquired on a flow cytometer.
  • [MeSH-major] Burkitt Lymphoma / immunology. Lymphocyte Activation. Malaria, Falciparum / complications. Malaria, Falciparum / immunology. Receptors, Antigen, T-Cell, gamma-delta / metabolism. T-Lymphocyte Subsets / immunology
  • [MeSH-minor] Child. Child, Preschool. Endemic Diseases. Female. Ghana / epidemiology. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] FEMS Microbiol Immunol. 1991 Aug;3(4):219-27 [1931134.001]
  • [Cites] J Immunol. 1992 Dec 15;149(12):3984-9 [1334108.001]
  • [Cites] J Immunol Methods. 1993 Jan 4;157(1-2):135-42 [8423356.001]
  • [Cites] Am J Trop Med Hyg. 1994 Sep;51(3):372-9 [7524374.001]
  • [Cites] Eur J Immunol. 1994 Dec;24(12):3199-204 [7528674.001]
  • [Cites] J Immunol. 1997 Jan 1;158(1):464-74 [8977224.001]
  • [Cites] Infect Immun. 1996 Oct;64(10):4359-62 [8926112.001]
  • [Cites] Pediatr Hematol Oncol. 1999 Mar-Apr;16(2):149-58 [10100275.001]
  • [Cites] Am J Trop Med Hyg. 1991 May;44(5):571-7 [2063961.001]
  • [Cites] Int Immunol. 2000 Jun;12(6):797-805 [10837407.001]
  • [Cites] Infect Immun. 2001 May;69(5):3190-6 [11292740.001]
  • [Cites] J Natl Cancer Inst. 1969 Jan;42(1):19-28 [4303830.001]
  • [Cites] Am J Med. 1970 Mar;48(3):279-85 [4190958.001]
  • [Cites] Trans R Soc Trop Med Hyg. 1977;71(5):408-10 [304268.001]
  • [Cites] Clin Exp Immunol. 1978 Apr;32(1):41-5 [352584.001]
  • [Cites] Nature. 1978 Aug 24;274(5673):756-61 [210392.001]
  • [Cites] Int J Cancer. 1978 Dec;22(6):662-8 [214405.001]
  • [Cites] Nature. 1984 Nov 29-Dec 5;312(5993):398 [6095098.001]
  • [Cites] Nature. 1984 Nov 29-Dec 5;312(5993):449-50 [6095104.001]
  • [Cites] J Clin Oncol. 1987 Aug;5(8):1262-74 [3114436.001]
  • [Cites] Eur J Immunol. 1991 May;21(5):1249-53 [1674690.001]
  • (PMID = 17521425.001).
  • [ISSN] 1475-2875
  • [Journal-full-title] Malaria journal
  • [ISO-abbreviation] Malar. J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Receptors, Antigen, T-Cell, gamma-delta
  • [Other-IDs] NLM/ PMC1894981
  •  go-up   go-down


Advertisement
4. Jacobs P, Wood L, Armitage JO: Proceedings of the 12th Biennial Congress -- South African Lymphoma Study Group. Transfus Apher Sci; 2007 Aug;37(1):27-9
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proceedings of the 12th Biennial Congress -- South African Lymphoma Study Group.
  • [MeSH-major] Lymphoma

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17881292.001).
  • [ISSN] 1473-0502
  • [Journal-full-title] Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis
  • [ISO-abbreviation] Transfus. Apher. Sci.
  • [Language] eng
  • [Publication-type] Congresses; Editorial
  • [Publication-country] England
  •  go-up   go-down


5. Jacobs P, Wood L: Lymphoma--the immune system in disarray Theme for the 11th Congress of the South African Lymphoma Study Group meeting. Transfus Apher Sci; 2005 Feb;32(1):21-3
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphoma--the immune system in disarray Theme for the 11th Congress of the South African Lymphoma Study Group meeting.
  • [MeSH-major] Immune System / pathology. Leukemia / immunology. Lymphoma / immunology. Lymphoproliferative Disorders / immunology

  • MedlinePlus Health Information. consumer health - Immune System and Disorders.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15737869.001).
  • [ISSN] 1473-0502
  • [Journal-full-title] Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis
  • [ISO-abbreviation] Transfus. Apher. Sci.
  • [Language] eng
  • [Publication-type] Congresses; Editorial
  • [Publication-country] England
  •  go-up   go-down


6. Koffi KG, N'dathz E, Tolo A, Nanho DC, Meite N, Ayemou R, Kouehion P, Sanogo I: [Rare localisations of endemic Burkitt lymphoma: about 21 cases observed in the Haematology Department of the University Hospital of Yopougon Abidjan]. Sante; 2010 Apr-Jun;20(2):69-72

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Rare localisations of endemic Burkitt lymphoma: about 21 cases observed in the Haematology Department of the University Hospital of Yopougon Abidjan].
  • [Transliterated title] Localisations exceptionnelles du Lymphome endémique de Burkitt (à propos de 21 cas vus en Côte d'Ivoire).
  • In this retrospective study, we analysed rare localisations of Burkitt lymphoma observed in the Haematology Department of the University Hospital of Yopougon Abidjan.
  • Over a 10-year study period, we saw 106 patients with Burkitt lymphoma, 21 with unusual localisations.
  • There were 8 cases of primary Burkitt lymphoma in a rare localisation and 13 cases of unusual localisations of secondary lymphomas.
  • In conclusion, the rare forms of Burkitt lymphoma are non-specific and can be mistaken for other solid tumours.
  • Diagnosis should thus be based on histochemical analysis.
  • [MeSH-major] Burkitt Lymphoma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20685641.001).
  • [ISSN] 1157-5999
  • [Journal-full-title] Santé (Montrouge, France)
  • [ISO-abbreviation] Sante
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


7. Tang W, Harmon P, Gulley ML, Mwansambo C, Kazembe PN, Martinson F, Wokocha C, Kenney SC, Hoffman I, Sigel C, Maygarden S, Hoffman M, Shores C: Viral response to chemotherapy in endemic burkitt lymphoma. Clin Cancer Res; 2010 Apr 1;16(7):2055-64
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Viral response to chemotherapy in endemic burkitt lymphoma.
  • We studied whether cyclophosphamide chemotherapy induces EBV to switch from latent to lytic phases of infection in a series of EBV-associated Burkitt lymphomas.
  • EXPERIMENTAL DESIGN: Children with first presentation of an expanding, solid maxillary or mandibular mass consistent with Burkitt lymphoma underwent fine-needle aspiration just prior to the initiation of cyclophosphamide therapy and again 1 to 5 days later.
  • RESULTS: Among 21 lymphomas expressing EBER prior to chemotherapy, 9 of 10 still expressed EBER on day 1 after therapy whereas only 2 of 11 (18%) specimens still expressed EBER at days 3 to 5, implying that chemotherapy was fairly effective at eliminating latently infected cells.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 AACR.
  • [Cites] J Virol. 2000 Nov;74(21):10223-8 [11024153.001]
  • [Cites] Haematologica. 2009 Nov;94(11):1618-22 [19608677.001]
  • [Cites] Antimicrob Agents Chemother. 2001 Jul;45(7):2082-91 [11408227.001]
  • [Cites] Transplantation. 2002 Jan 27;73(2):271-9 [11821743.001]
  • [Cites] Cancer Res. 2002 Mar 15;62(6):1920-6 [11912175.001]
  • [Cites] Med Pediatr Oncol. 2003 Jan;40(1):23-5 [12426682.001]
  • [Cites] Crit Rev Oncol Hematol. 2003 Jan;45(1):1-36 [12482570.001]
  • [Cites] Med Sci Monit. 2003 Jan;9(1):HY1-9 [12552250.001]
  • [Cites] Cancer Res. 2003 Mar 1;63(5):965-71 [12615710.001]
  • [Cites] Hematol Oncol Clin North Am. 2003 Jun;17(3):697-702, v-vi [12852651.001]
  • [Cites] J Virol. 2004 Feb;78(4):1893-902 [14747554.001]
  • [Cites] J Clin Oncol. 2004 Apr 15;22(8):1373-81 [15007085.001]
  • [Cites] Eur J Biochem. 2004 May;271(10):1895-905 [15128299.001]
  • [Cites] Diagn Mol Pathol. 2004 Jun;13(2):61-8 [15167006.001]
  • [Cites] J Clin Oncol. 2004 Aug 1;22(15):3053-60 [15284255.001]
  • [Cites] J Mol Diagn. 2004 Nov;6(4):378-85 [15507678.001]
  • [Cites] EMBO J. 1986 Oct;5(10):2599-607 [3023050.001]
  • [Cites] Cancer Res. 1989 Jan 1;49(1):1-7 [2491747.001]
  • [Cites] J Virol. 1989 Apr;63(4):1729-36 [2538653.001]
  • [Cites] J Virol. 1989 Jul;63(7):3109-16 [2542618.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Aug 1;88(15):6550-4 [1713681.001]
  • [Cites] Semin Cancer Biol. 1992 Oct;3(5):285-95 [1335792.001]
  • [Cites] Blood. 1995 Jul 15;86(2):659-65 [7605996.001]
  • [Cites] Cancer Res. 1996 Mar 1;56(5):969-72 [8640787.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Aug 20;93(17):9194-9 [8799177.001]
  • [Cites] Semin Cancer Biol. 1996 Aug;7(4):217-26 [8946606.001]
  • [Cites] Hum Gene Ther. 1998 May 20;9(8):1131-41 [9625252.001]
  • [Cites] J Virol. 1998 Oct;72(10):7978-84 [9733836.001]
  • [Cites] J Virol. 1998 Nov;72(11):9323-8 [9765483.001]
  • [Cites] Int J Cancer. 1999 Mar 31;81(1):6-11 [10077144.001]
  • [Cites] Cancer Res. 1999 Apr 1;59(7):1485-91 [10197618.001]
  • [Cites] Cancer. 1961 Mar-Apr;14:258-69 [14448554.001]
  • [Cites] J Natl Cancer Inst. 2004 Nov 17;96(22):1691-702 [15547182.001]
  • [Cites] Mod Pathol. 2005 Apr;18(4):519-27 [15696119.001]
  • [Cites] J Biol Chem. 2006 Nov 10;281(45):33871-80 [16956891.001]
  • [Cites] J Virol. 2007 Jan;81(2):1037-42 [17079287.001]
  • [Cites] Blood. 2007 Mar 15;109(6):2571-8 [17119113.001]
  • [Cites] Adv Cancer Res. 2007;97:81-109 [17419942.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2007;:277-84 [18024641.001]
  • [Cites] J Virol Methods. 2008 Jan;147(1):26-36 [17870188.001]
  • [Cites] FEBS Lett. 2008 Mar 5;582(5):705-9 [18258198.001]
  • [Cites] Trop Doct. 2008 Jan;38(1):7-11 [18302850.001]
  • [Cites] J Virol. 2008 May;82(10):4706-19 [18337569.001]
  • [Cites] J Mol Diagn. 2008 Jul;10(4):279-92 [18556771.001]
  • [Cites] Med Oncol. 2009;26(1):1-9 [18461290.001]
  • [Cites] Cancer Biol Ther. 2009 Jun;8(11):987-95 [19448399.001]
  • [Cites] J Virol. 2009 Oct;83(20):10694-709 [19656890.001]
  • [Cites] Cancer Res. 2000 Oct 15;60(20):5781-8 [11059774.001]
  • (PMID = 20233888.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA066519; United States / NCI NIH HHS / CA / R01 CA058853; United States / NCI NIH HHS / CA / CA066519-16; United States / NCI NIH HHS / CA / R01-CA66519; United States / NCI NIH HHS / CA / R01 CA066519-16
  • [Publication-type] Clinical Trial; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / DNA, Viral; 8N3DW7272P / Cyclophosphamide
  • [Other-IDs] NLM/ NIHMS179000; NLM/ PMC2848899
  •  go-up   go-down


8. Ogwang MD, Bhatia K, Biggar RJ, Mbulaiteye SM: Incidence and geographic distribution of endemic Burkitt lymphoma in northern Uganda revisited. Int J Cancer; 2008 Dec 1;123(11):2658-63
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence and geographic distribution of endemic Burkitt lymphoma in northern Uganda revisited.
  • Endemic Burkitt lymphoma (BL) is etiologically associated with Epstein-Barr virus and ecologically linked to Plasmodium falciparum malaria.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • [Cites] Br J Cancer. 2000 May;82(9):1585-92 [10789729.001]
  • [Cites] Hum Genet. 1997 Nov;101(1):1-5 [9385359.001]
  • [Cites] Pediatr Blood Cancer. 2008 Jun;50(6):1125-6 [18300307.001]
  • [Cites] Lancet Oncol. 2008 Apr;9(4):319 [18380064.001]
  • [Cites] Int J Cancer. 2008 Mar 15;122(6):1319-23 [18000823.001]
  • [Cites] Trop Med Int Health. 2007 Aug;12(8):936-43 [17697088.001]
  • [Cites] J Natl Cancer Inst. 2007 Jun 20;99(12):962-72 [17565153.001]
  • [Cites] Int J Cancer. 2007 Jan 1;120(1):121-7 [17019706.001]
  • [Cites] Am J Trop Med Hyg. 2006 Aug;75(2):219-25 [16896122.001]
  • [Cites] Nat Genet. 1993 Sep;5(1):56-61 [8220424.001]
  • [Cites] IARC Sci Publ. 1985;(60):177-86 [3905588.001]
  • [Cites] IARC Sci Publ. 1985;(60):155-64 [4065944.001]
  • [Cites] IARC Sci Publ. 1984;(63):665-74 [6536627.001]
  • [Cites] J Clin Immunol. 1985 Mar;5(2):65-77 [3886684.001]
  • [Cites] Int J Cancer. 1980 Feb 15;25(2):197-203 [7390649.001]
  • [Cites] Int J Cancer. 1979 Mar 15;23(3):330-6 [437917.001]
  • [Cites] N Engl J Med. 2006 Jun 8;354(23):2419-30 [16760442.001]
  • [Cites] Int J Cancer. 2006 Feb 15;118(4):985-90 [16106415.001]
  • [Cites] Community Dent Health. 2005 Sep;22(3):146-50 [16161877.001]
  • [Cites] West Afr J Med. 2005 Apr-Jun;24(2):139-42 [16092315.001]
  • [Cites] Early Hum Dev. 2005 Jan;81(1):123-9 [15707724.001]
  • [Cites] Nat Rev Microbiol. 2005 Feb;3(2):182-7 [15685227.001]
  • [Cites] Lancet Oncol. 2004 Dec;5(12):738-46 [15581545.001]
  • [Cites] Br J Surg. 1958 Nov;46(197):218-23 [13628987.001]
  • [Cites] J Acquir Immune Defic Syndr. 2003 Apr 15;32(5):527-33 [12679705.001]
  • [Cites] Hematol Oncol Clin North Am. 2003 Jun;17(3):673-96, v [12852650.001]
  • [Cites] Br J Cancer. 1969 Jun;23(2):235-46 [5788031.001]
  • [Cites] Br Med J. 1971 May 29;2(5760):491-2 [4325452.001]
  • [Cites] Lancet. 1974 Jul 6;2(7871):19-22 [4134408.001]
  • [Cites] Ann Intern Med. 1975 Jul;83(1):31-6 [1147436.001]
  • [Cites] Br J Cancer. 1977 May;35(5):668-73 [861150.001]
  • [Cites] Br J Cancer. 1978 Jan;37(1):109-22 [619954.001]
  • [Cites] Nature. 1978 Aug 24;274(5673):756-61 [210392.001]
  • [Cites] AIDS. 2000 Dec 22;14(18):2929-36 [11153674.001]
  • (PMID = 18767045.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / / Z01 CP010150-08; United States / NCI NIH HHS / CP / N02CP31003; United States / NCI NIH HHS / CP / N02-CP-31003; United States / NCI NIH HHS / CA / N01CO12400; United States / NCI NIH HHS / CO / N01-CO-12400
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS54919; NLM/ PMC2574984
  •  go-up   go-down


9. Armitage JO, German Hodgkin Study Group, Diehl V, Engert A, Jacobs P, Groote Schuur Hospitals Teaching Group, Wood L: Proceedings of the 13th biennial South African Lymphoma Study Group Meeting--Cape Town October 2008. Transfus Apher Sci; 2010 Apr;42(2):125-8
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proceedings of the 13th biennial South African Lymphoma Study Group Meeting--Cape Town October 2008.
  • [MeSH-major] Lymphoma

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20219432.001).
  • [ISSN] 1473-0502
  • [Journal-full-title] Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis
  • [ISO-abbreviation] Transfus. Apher. Sci.
  • [Language] eng
  • [Publication-type] Congresses; Editorial
  • [Publication-country] England
  •  go-up   go-down


10. Olowu WA, Adelusola KA, Badmos KB, Aina OJ: Autopsy diagnosis of endemic burkitt lymphoma as the primary etiology of acute renal failure in children. Pediatr Hematol Oncol; 2005 Jun;22(4):315-21

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autopsy diagnosis of endemic burkitt lymphoma as the primary etiology of acute renal failure in children.
  • Two cases of Burkitt lymphoma are reported who presented atypically with acute renal failure and significant proteinuria as initial features of the lymphoma.
  • The cases underscore the need for high index of suspicion for Burkitt lymphoma in any child with rapidly enlarging kidneys and acute renal failure of obscured origin in parts of the world where Burkitt lymphoma is endemic.
  • [MeSH-major] Acute Kidney Injury / etiology. Burkitt Lymphoma / diagnosis
  • [MeSH-minor] Adolescent. Autopsy. Child, Preschool. Diagnosis, Differential. Endemic Diseases. Fatal Outcome. Female. Humans. Kidney Medulla / pathology. Neoplasm Invasiveness

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16020119.001).
  • [ISSN] 0888-0018
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


11. Harrison TM, McKnight CA, Sikarskie JG, Kitchell BE, Garner MM, Raymond JT, Fitzgerald SD, Valli VE, Agnew D, Kiupel M: Malignant lymphoma in african lions (panthera leo). Vet Pathol; 2010 Sep;47(5):952-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant lymphoma in african lions (panthera leo).
  • Malignant lymphoma has become an increasingly recognized problem in African lions (Panthera leo).
  • Eleven African lions (9 male and 2 female) with clinical signs and gross and microscopic lesions of malignant lymphoma were evaluated in this study.
  • Immunohistochemically, 10 of the 11 lions had T-cell lymphomas (CD3(+), CD79a(-)), and 1 lion was diagnosed with a B-cell lymphoma (CD3(-), CD79a(+)).
  • The spleen appeared to be the primary site of neoplastic growth in all T-cell lymphomas, with involvement of the liver (6/11) and regional lymph nodes (5/11) also commonly observed.
  • The B-cell lymphoma affected the peripheral lymph nodes, liver, and spleen.
  • According to the current veterinary and human World Health Organization classification of hematopoietic neoplasms, T-cell lymphoma subtypes included peripheral T-cell lymphoma (4/11), precursor (acute) T-cell lymphoblastic lymphoma/leukemia (2/11), chronic T-cell lymphocytic lymphoma/leukemia (3/11), and T-zone lymphoma (1/11).
  • The single B-cell lymphoma subtype was consistent with diffuse large B-cell lymphoma.
  • Feline leukemia virus (FeLV) and feline immunodeficiency virus (FIV) testing by immunohistochemistry on sections of malignant lymphoma was negative for all 11 lions.
  • In contrast to domestic and exotic cats, in which B-cell lymphomas are more common than T-cell lymphomas, African lions in this study had malignant lymphomas that were primarily of T-cell origin.
  • Neither FeLV nor FIV, important causes of malignant lymphoma in domestic cats, seems to be significant in the pathogenesis of malignant lymphoma in African lions.
  • [MeSH-major] Lions. Lymphoma / veterinary. Lymphoma, B-Cell / veterinary. Lymphoma, T-Cell / veterinary

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20610770.001).
  • [ISSN] 1544-2217
  • [Journal-full-title] Veterinary pathology
  • [ISO-abbreviation] Vet. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Rainey JJ, Rochford R, Sumba PO, Kowuor D, Wilson ML, Moormann AM: Family environment is associated with endemic Burkitt lymphoma: a population-based case-control study. Am J Trop Med Hyg; 2008 Feb;78(2):338-43
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Family environment is associated with endemic Burkitt lymphoma: a population-based case-control study.
  • Endemic Burkitt's lymphoma (eBL) has been linked to Epstein-Barr virus and holoendemic Plasmodium falciparum malaria.
  • These co-infections, however, are insufficient to explain the non-random occurrence of Endemic Burkitt's lymphoma within Equatorial Africa.
  • To explore whether this distribution could be explained by household characteristics and family environment, we conducted a case-control study using 41 hospitalized incident endemic Burkitt's lymphoma cases and 91 healthy controls identified through a population-based multistage cluster-sampling scheme in Nyanza Province, Kenya.
  • In a multivariate analysis, odds ratios associated with having one, two, and three or more younger siblings compared with none were 0.28 (90% CI: 0.09, 0.83), 0.59 (90% CI: 0.16, 2.23) and 0.15 (90% CI: 0.03, 0.67) respectively, suggesting that children with endemic Burkitt's lymphoma were more likely than controls to be last-born.
  • Children with endemic Burkitt's lymphoma were also more likely to live in non-monogamous families (OR=3.12, 90% CI:1.19, 8.17) and to have at least one deceased parent (OR=3.38, 90% CI: 1.18, 9.64).
  • Household characteristics, especially sibship relationships, may contribute to endemic Burkitt's lymphoma and therefore warrant further study.
  • [MeSH-major] Burkitt Lymphoma / epidemiology. Endemic Diseases. Family Characteristics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18256442.001).
  • [ISSN] 0002-9637
  • [Journal-full-title] The American journal of tropical medicine and hygiene
  • [ISO-abbreviation] Am. J. Trop. Med. Hyg.
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / K08 AI051565
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


13. Kurokawa M, Andela V, Ghosh S, Barreto JE, Harrington W: Zidovudine: a targeted therapy for endemic Burkitt's lymphoma. East Afr Med J; 2005 Sep;82(9 Suppl):S150-4
Hazardous Substances Data Bank. ZIDOVUDINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Zidovudine: a targeted therapy for endemic Burkitt's lymphoma.
  • BACKGROUND: Although cyclophosphamide based regimens can produce remission rates approaching 60 to 80% in endemic Burkitts lymphoma, relapses and refractory disease are fairly common in developing countries, due to advanced stage disease and cost-constraints in the implementation of optimal chemotherapeutic protocols.
  • OBJECTIVE: To evaluate an affordable, tolerable and targeted approach to chemotherapy for endemic Burkitt's lymphoma as would be desirable in resource poor settings such as Africa.
  • DATA EXTRACTION: A systematic review to identify studies relating to Zidovudine, EBV+ and Burkitt's lymphoma, indicating antiviral agents zidovudine targeting BL in a unique and novel mechanisms.
  • CONCLUSION: Our data suggests that the incorporation of Zidovudine into Burkitt's regimens may enhance tumour kill and abbreviate the duration of treatment necessary for this disease.
  • Furthermore, the addition of the widely available and inexpensive agent hydroxyurea, markedly potentiates the tumorcidal activity of Zidovudine in Epstein Barr virus positive Burkitt's lymphomas.
  • [MeSH-major] Antiviral Agents / therapeutic use. Burkitt Lymphoma / drug therapy. Epstein-Barr Virus Infections / drug therapy. Zidovudine / therapeutic use

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16619691.001).
  • [ISSN] 0012-835X
  • [Journal-full-title] East African medical journal
  • [ISO-abbreviation] East Afr Med J
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis
  • [Publication-country] Kenya
  • [Chemical-registry-number] 0 / Antiviral Agents; 4B9XT59T7S / Zidovudine
  •  go-up   go-down


14. Chene A, Donati D, Orem J, Mbidde ER, Kironde F, Wahlgren M, Bejarano MT: Endemic Burkitt's lymphoma as a polymicrobial disease: new insights on the interaction between Plasmodium falciparum and Epstein-Barr virus. Semin Cancer Biol; 2009 Dec;19(6):411-20
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endemic Burkitt's lymphoma as a polymicrobial disease: new insights on the interaction between Plasmodium falciparum and Epstein-Barr virus.
  • Despite the well-established relationship between endemic Plasmodium falciparum malaria and Epstein-Barr virus (EBV) infection in the genesis of endemic Burkitt's lymphoma (eBL), very little research has examined the interaction between these two pathogens. eBL, the most prevalent childhood cancer in equatorial Africa where malaria is holoendemic, is a high-grade B cell lymphoma characterized by a c-myc translocation and the consistent presence of EBV.
  • African children are infected early in life and most have sero-converted by 3 years of age while sero-conversion tends to occur later in developed countries.
  • Following the observation of EBV reactivation in children living in malaria endemic areas and its relationship with acute malaria infection, we identified the cystein-rich inter-domain region 1 alpha (CIDR1 alpha) of the Plasmodium falciparum membrane protein 1 as a polyclonal B cell activator.
  • The increased viral load and the concomitant polyclonal B cell activation with enhanced B cell survival may augment the risk of eBL development in children living in malaria-endemic areas.
  • [MeSH-major] Burkitt Lymphoma / etiology. Epstein-Barr Virus Infections / complications. Herpesvirus 4, Human / pathogenicity. Malaria, Falciparum / complications. Plasmodium falciparum / pathogenicity

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19897039.001).
  • [ISSN] 1096-3650
  • [Journal-full-title] Seminars in cancer biology
  • [ISO-abbreviation] Semin. Cancer Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 100
  •  go-up   go-down


15. Bell AI, Groves K, Kelly GL, Croom-Carter D, Hui E, Chan AT, Rickinson AB: Analysis of Epstein-Barr virus latent gene expression in endemic Burkitt's lymphoma and nasopharyngeal carcinoma tumour cells by using quantitative real-time PCR assays. J Gen Virol; 2006 Oct;87(Pt 10):2885-90
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of Epstein-Barr virus latent gene expression in endemic Burkitt's lymphoma and nasopharyngeal carcinoma tumour cells by using quantitative real-time PCR assays.
  • When the new assays were used to screen a collection of endemic Burkitt's lymphoma tumours, abundant Qp-driven EBNA1 expression was found, whereas the other latent transcripts (with the exception of LMP2A) were either absent or detectable only at trace levels.
  • [MeSH-major] Burkitt Lymphoma / virology. Gene Expression Regulation, Viral. Herpesvirus 4, Human / genetics. Nasopharyngeal Neoplasms / virology. Virus Latency / genetics

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16963746.001).
  • [ISSN] 0022-1317
  • [Journal-full-title] The Journal of general virology
  • [ISO-abbreviation] J. Gen. Virol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / RNA, Viral
  •  go-up   go-down


16. Tolo-Diebkilé A, Koffi GK, Nanho CD, Sawadogo D, Kouakou B, Siransi-Bogui L, Ayémou R, Sanogo I: [Evaluation of the protocol CMA reinforced in the treatment of endemic Burkitt lymphoma at CHU of Yopougon in Abidjan]. Bull Cancer; 2010 May;97(5):507-9
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Evaluation of the protocol CMA reinforced in the treatment of endemic Burkitt lymphoma at CHU of Yopougon in Abidjan].
  • [Transliterated title] Evaluation du protocole CMA renforcé dans le traitement du lymphome de Burkitt endémique au CHU de Yopougon à Abidjan.
  • We report the results of the protocol CMA (cyclophosphamide, methotrexate, Aracytine) reinforced of 26 patients affected by Burkitt lymphoma in facial-maxillary localisation, in a retrospective study from January 2000 till December 2007 and prospective from January till September 2008.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / drug therapy. Facial Neoplasms / drug therapy. Maxillary Neoplasms / drug therapy

  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20071300.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 8N3DW7272P / Cyclophosphamide; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


17. Moormann AM, Heller KN, Chelimo K, Embury P, Ploutz-Snyder R, Otieno JA, Oduor M, Münz C, Rochford R: Children with endemic Burkitt lymphoma are deficient in EBNA1-specific IFN-gamma T cell responses. Int J Cancer; 2009 Apr 1;124(7):1721-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Children with endemic Burkitt lymphoma are deficient in EBNA1-specific IFN-gamma T cell responses.
  • Endemic Burkitt lymphoma (eBL) is the most common childhood cancer in equatorial Africa and is linked to Epstein-Barr virus (EBV) and Plasmodium falciparum coinfections early in life.
  • In addition, CD4(+) T cell responses to a malaria protein, merozoite surface protein 1, were present in lymphoma patients.
  • This study demonstrates a selective loss of EBNA1-specific T cell responses in children with eBL and suggests a potential immunotherapeutic target for this EBV-associated lymphoma.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Philos Trans R Soc Lond B Biol Sci. 2001 Apr 29;356(1408):461-73 [11313005.001]
  • [Cites] J Immunol. 2008 Feb 1;180(3):1451-61 [18209040.001]
  • [Cites] Science. 2003 Sep 5;301(5638):1371-4 [12958359.001]
  • [Cites] J Virol. 2003 Nov;77(22):12088-104 [14581546.001]
  • [Cites] Infect Immun. 2003 Dec;71(12):6766-74 [14638762.001]
  • [Cites] J Exp Med. 2004 Feb 16;199(4):459-70 [14769850.001]
  • [Cites] Tissue Antigens. 2004 Apr;63(4):293-325 [15009803.001]
  • [Cites] IARC Sci Publ. 1985;(60):165-76 [2998987.001]
  • [Cites] Nature. 1995 Jun 22;375(6533):685-8 [7540727.001]
  • [Cites] Immunity. 1997 Dec;7(6):791-802 [9430224.001]
  • [Cites] Nature. 1999 Jul 1;400(6739):73-7 [10403251.001]
  • [Cites] East Afr Med J. 2004 Aug;(8 Suppl):S68-77 [15622605.001]
  • [Cites] J Infect Dis. 2005 Apr 15;191(8):1233-8 [15776368.001]
  • [Cites] Blood. 2005 Nov 1;106(9):3166-74 [16014568.001]
  • [Cites] Nat Immunol. 2006 Feb;7(2):165-72 [16415871.001]
  • [Cites] J Clin Microbiol. 2006 Apr;44(4):1459-67 [16597877.001]
  • [Cites] Int J Cancer. 2007 Jan 1;120(1):121-7 [17019706.001]
  • [Cites] Blood. 2007 Feb 1;109(3):1138-46 [16985171.001]
  • [Cites] J Infect Dis. 2007 Mar 15;195(6):799-808 [17299709.001]
  • [Cites] J Immunol. 2002 Aug 1;169(3):1593-603 [12133989.001]
  • (PMID = 19089927.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA108609; United States / NIAID NIH HHS / AI / AI4390; United States / FIC NIH HHS / TW / D43 TW006576; United States / NCI NIH HHS / CA / R01 CA101741; United States / NIAID NIH HHS / AI / U01 AI043906; United States / NIAID NIH HHS / AI / R01 AI043906; United States / NCI NIH HHS / CA / R01 CA134051; United States / NIAID NIH HHS / AI / K08 AI051565; United States / NCI NIH HHS / CA / CA101741; United States / FIC NIH HHS / TW / D43 TW006576-05; United States / NIAID NIH HHS / AI / K08-AI51565; United States / NIAID NIH HHS / AI / K08 AI051565-05; United States / NCI NIH HHS / CA / CA108609; United States / NCI NIH HHS / CA / R01 CA102667
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / EBV-encoded nuclear antigen 1; 0 / Epstein-Barr Virus Nuclear Antigens; 0 / Immunoglobulin G; 82115-62-6 / Interferon-gamma
  • [Other-IDs] NLM/ NIHMS98574; NLM/ PMC2708320
  •  go-up   go-down


18. De Falco G, Leucci E, Lenze D, Piccaluga PP, Claudio PP, Onnis A, Cerino G, Nyagol J, Mwanda W, Bellan C, Hummel M, Pileri S, Tosi P, Stein H, Giordano A, Leoncini L: Gene-expression analysis identifies novel RBL2/p130 target genes in endemic Burkitt lymphoma cell lines and primary tumors. Blood; 2007 Aug 15;110(4):1301-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene-expression analysis identifies novel RBL2/p130 target genes in endemic Burkitt lymphoma cell lines and primary tumors.
  • Burkitt lymphoma (BL) is a B-cell tumor whose characteristic gene aberration is the translocation t(8;14), which determines c-myc overexpression.
  • We then monitored their expression in primary tumors of endemic BL as well, demonstrating that their expression resembled those of the BL cell lines.
  • [MeSH-major] Biomarkers, Tumor / genetics. Burkitt Lymphoma / genetics. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Mutation / genetics. Retinoblastoma-Like Protein p130 / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17485552.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA60999
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RBL2 protein, human; 0 / Retinoblastoma-Like Protein p130
  •  go-up   go-down


19. Rainey JJ, Omenah D, Sumba PO, Moormann AM, Rochford R, Wilson ML: Spatial clustering of endemic Burkitt's lymphoma in high-risk regions of Kenya. Int J Cancer; 2007 Jan 1;120(1):121-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spatial clustering of endemic Burkitt's lymphoma in high-risk regions of Kenya.
  • Endemic Burkitt's lymphoma (eBL), the most common childhood cancer in sub-Saharan Africa, occurs at a high incidence in western Kenya, a region that also experiences holoendemic malaria.
  • [MeSH-major] Burkitt Lymphoma / epidemiology. Endemic Diseases

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17019706.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / K08 AI51565
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


20. Gutiérrez-García L, Medina Ramos N, García Rodríguez R, Barber MA, Arias MD, García JA: Bilateral ovarian Burkitt's lymphoma. Eur J Gynaecol Oncol; 2009;30(2):231-3
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral ovarian Burkitt's lymphoma.
  • Primary ovarian lymphoma is a rare entity.
  • Histology confirmed Epstein-Barr virus-positive bilateral Burkitt's lymphoma.
  • Endemic Burkitt's lymphoma has a predilection for the female genital tract, manifesting itself clinically as a pelvic mass and less frequently as a menstrual disorder.
  • It is a rare entity in our environment but should be kept in mind when treating patients of African origin.
  • [MeSH-major] Burkitt Lymphoma / pathology. Ovarian Neoplasms / pathology

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19480266.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


21. Magrath I: Lessons from clinical trials in African Burkitt lymphoma. Curr Opin Oncol; 2009 Sep;21(5):462-8
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lessons from clinical trials in African Burkitt lymphoma.
  • The present review focuses on the treatment of an AIDS-defining malignancy, Burkitt lymphoma, since the discovery of the tumor in 1958 to provide a backdrop to the increasing necessity of dealing with AIDS-associated Burkitt lymphoma in Africa.
  • RECENT FINDINGS: In Africa, it appears that AIDS-associated Burkitt lymphoma is increasing, but although treatment outcome is presently poor, the demonstration that highly active antiretroviral therapy permits the same treatment results to those in AIDS-unassociated Burkitt lymphoma provides hope for the future.
  • SUMMARY: In the 1960s, the extraordinary response of Burkitt lymphoma to chemotherapy provided considerable encouragement to pioneer oncologists.
  • The impact of the HIV epidemic on the epidemiology and treatment of African Burkitt lymphoma will receive increasing focus in the coming years.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / drug therapy. Lymphoma, AIDS-Related / drug therapy

  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19620863.001).
  • [ISSN] 1531-703X
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 64
  •  go-up   go-down


22. Rochford R, Cannon MJ, Moormann AM: Endemic Burkitt's lymphoma: a polymicrobial disease? Nat Rev Microbiol; 2005 02;3(2):182-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endemic Burkitt's lymphoma: a polymicrobial disease?
  • Endemic Burkitt's lymphoma is the most common childhood cancer in equatorial Africa.
  • [MeSH-major] Burkitt Lymphoma / etiology. Endemic Diseases. Epstein-Barr Virus Infections / physiopathology. Herpesvirus 4, Human / pathogenicity. Malaria, Falciparum / physiopathology. Plasmodium falciparum / pathogenicity

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15685227.001).
  • [ISSN] 1740-1526
  • [Journal-full-title] Nature reviews. Microbiology
  • [ISO-abbreviation] Nat. Rev. Microbiol.
  • [Language] eng
  • [Publication-type] Review
  • [Publication-country] England
  •  go-up   go-down


23. Rochford R, Feuer G, Orem J, Banura C, Katongole-Mbidde E, Mwanda WO, Moormann A, Harrington WJ, Remick SC: Strategies to overcome myelotoxic therapy for the treatment of Burkitt's and AIDS-related non-Hodgkin's lymphoma. East Afr Med J; 2005 Sep;82(9 Suppl):S155-60
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Strategies to overcome myelotoxic therapy for the treatment of Burkitt's and AIDS-related non-Hodgkin's lymphoma.
  • OBJECTIVES: To develop effective non-myelotoxic therapies for Burkitt's Lymphoma (BL) and AIDS-related non-Hodgkin's lymphoma.
  • CONCLUSION: Myelotoxic death rates using multi-agent induction chemotherapy approach 25% for endemic Burkitt's lymphoma and range between 20% to 60% for AIDS-related malignancy.
  • Investigations and alternative approaches that lessen or circumvent myelotoxicity of traditional cytotoxic chemotherapy for the management of Burkitt's lymphoma and AIDS-related non-Hodgkin's lymphoma in the resource-constrained setting are warranted.
  • This can be achieved by developing targeted anti-viral and other strategies, such as the use of bryostatin 1 and vincristine, and by developing a preclinical mouse model to frame the clinical rationale for a pilot trial of metronomic therapy for the treatment of Burkitt's and AIDS-related lymphoma.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Burkitt Lymphoma / drug therapy. Lymphoma, AIDS-Related / drug therapy. Macrolides / therapeutic use. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16619692.001).
  • [ISSN] 0012-835X
  • [Journal-full-title] East African medical journal
  • [ISO-abbreviation] East Afr Med J
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Kenya
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Bryostatins; 0 / Macrolides; 37O2X55Y9E / bryostatin 1; 5J49Q6B70F / Vincristine
  • [Number-of-references] 38
  •  go-up   go-down


24. Asito AS, Piriou E, Odada PS, Fiore N, Middeldorp JM, Long C, Dutta S, Lanar DE, Jura WG, Ouma C, Otieno JA, Moormann AM, Rochford R: Elevated anti-Zta IgG levels and EBV viral load are associated with site of tumor presentation in endemic Burkitt's lymphoma patients: a case control study. Infect Agent Cancer; 2010;5:13
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Elevated anti-Zta IgG levels and EBV viral load are associated with site of tumor presentation in endemic Burkitt's lymphoma patients: a case control study.
  • BACKGROUND: Endemic Burkitt's lymphoma (BL) is an extranodal tumor appearing predominantly in the jaw in younger children while abdominal tumors predominate with increasing age.
  • Previous studies have identified elevated levels of antibodies to Plasmodium falciparum schizont extracts and Epstein-Barr virus (EBV) viral capsid antigens (VCA) in endemic BL relative to malaria exposed controls.
  • METHODS: We used a suspension bead Luminex assay to measure the IgG levels against EBV antigens, VCA, EAd, EBNA-1 and Zta as well as P. falciparum MSP-1, LSA-1, and AMA-1 antigens in children with BL (n = 32) and in population-based age-and sex-matched controls (n = 25) from a malaria endemic region in Western Kenya with high incidence of BL.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Cancer Biol. 2009 Dec;19(6):377-88 [19619657.001]
  • [Cites] J Gen Virol. 1995 Jun;76 ( Pt 6):1393-400 [7540196.001]
  • [Cites] J Infect Dis. 1994 Jul;170(1):13-9 [8014488.001]
  • [Cites] Cancer. 1980 Mar 15;45(6):1507-15 [6244085.001]
  • [Cites] Nature. 1978 Aug 24;274(5673):756-61 [210392.001]
  • [Cites] Lancet. 1977 Feb 12;1(8007):335-8 [64861.001]
  • [Cites] Nat Rev Cancer. 2004 Oct;4(10):757-68 [15510157.001]
  • [Cites] Arch Pathol Lab Med. 2004 May;128(5):549-52 [15086279.001]
  • [Cites] Cytometry. 2002 Oct 15;50(5):239-42 [12360572.001]
  • [Cites] Int J Cancer. 2002 Jun 10;99(5):635-43 [12115495.001]
  • [Cites] Int J Cancer. 2009 Apr 1;124(7):1721-6 [19089927.001]
  • [Cites] Nat Rev Microbiol. 2008 Dec;6(12):913-24 [19008891.001]
  • [Cites] Clin Vaccine Immunol. 2008 Nov;15(11):1684-8 [18768669.001]
  • [Cites] Int J Cancer. 2008 Dec 1;123(11):2658-63 [18767045.001]
  • [Cites] PLoS One. 2008;3(6):e2505 [18560562.001]
  • [Cites] Int J Cancer. 2008 Mar 15;122(6):1319-23 [18000823.001]
  • [Cites] J Clin Virol. 2008 Feb;41(2):96-103 [18024156.001]
  • [Cites] AIDS. 2007 Oct 18;21(16):2141-9 [18090040.001]
  • [Cites] Trop Med Int Health. 2007 Aug;12(8):936-43 [17697088.001]
  • [Cites] Int J Cancer. 2007 Jan 1;120(1):121-7 [17019706.001]
  • [Cites] Singapore Med J. 2006 Sep;47(9):803-7 [16924363.001]
  • [Cites] J Infect Dis. 2005 Apr 15;191(8):1233-8 [15776368.001]
  • [Cites] Anticancer Res. 2004 Nov-Dec;24(6):4059-66 [15736452.001]
  • [Cites] Nat Rev Microbiol. 2005 Feb;3(2):182-7 [15685227.001]
  • [Cites] East Afr Med J. 2004 Aug;(8 Suppl):S111-6 [15622609.001]
  • [Cites] Int J Cancer. 1999 Mar 31;81(1):6-11 [10077144.001]
  • [Cites] J Med Virol. 1999 Apr;57(4):383-9 [10089051.001]
  • [Cites] J Infect Dis. 1999 May;179(5):1108-15 [10191211.001]
  • [Cites] Ann Med. 1998 Jun;30(3):249-59 [9677010.001]
  • [Cites] Pediatr Pathol Lab Med. 1997 May-Jun;17(3):391-400 [9185219.001]
  • [Cites] Blood. 1996 Jun 15;87(12):5279-86 [8652843.001]
  • [Cites] Blood. 1995 Jul 15;86(2):659-65 [7605996.001]
  • [Cites] J Med Virol. 2009 Jun;81(6):1088-93 [19382256.001]
  • (PMID = 20667138.001).
  • [ISSN] 1750-9378
  • [Journal-full-title] Infectious agents and cancer
  • [ISO-abbreviation] Infect. Agents Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA102667
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2923120
  •  go-up   go-down


25. Moormann AM, Chelimo K, Sumba OP, Lutzke ML, Ploutz-Snyder R, Newton D, Kazura J, Rochford R: Exposure to holoendemic malaria results in elevated Epstein-Barr virus loads in children. J Infect Dis; 2005 Apr 15;191(8):1233-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Perennial and intense malaria transmission (holoendemic malaria) and Epstein-Barr virus (EBV) infection are 2 cofactors in the pathogenesis of endemic Burkitt lymphoma (eBL).

  • Genetic Alliance. consumer health - Malaria.
  • MedlinePlus Health Information. consumer health - Malaria.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15776368.001).
  • [ISSN] 0022-1899
  • [Journal-full-title] The Journal of infectious diseases
  • [ISO-abbreviation] J. Infect. Dis.
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / K08 AI51565; United States / NIAID NIH HHS / AI / U01 AI43906
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


26. Lubega J: T-helper 1 versus T-helper 2 lymphocyte immunodysregulation is the central factor in genesis of Burkitt lymphoma: hypothesis. Infect Agent Cancer; 2007;2:10
HIV InSite. treatment guidelines - Malaria and HIV .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T-helper 1 versus T-helper 2 lymphocyte immunodysregulation is the central factor in genesis of Burkitt lymphoma: hypothesis.
  • BACKGROUND: The HIV epidemic has challenged our previous understanding of endemic Burkitt's lymphoma.
  • Despite the strong association of Burkitt's lymphoma and HIV infection in the Developed world, and against previous postulations that the cancer is due to immunosupression among African children, the HIV epidemic in the Malaria belt has not been associated with a corresponding increase in incidence of childhood Burkitt's lymphoma.
  • Even outside the context of HIV infection, there is substantial evidence for a strong but skewed immune response towards a TH2 response in genesis of Burkitt lymphoma.
  • PRESENTATION OF THE HYPOTHESIS: Rather than a global and/or profound immunosupression, the final common pathway in genesis of Burkitt's lymphoma is the dysregulation of the immune response towards a TH2 response dominated by B-lymphocytes, and the concomitant suppression of the TH1 cell-mediated immune surveillance, driven by various viral/parasitic/bacterial infections.
  • TESTING THE HYPOTHESIS: Case control studies comparing TH2 and TH1 immune responses in Burkitt lymphoma of different etiological types (sporadic, HIV-related, endemic and post-transplant) to demonstrate significant dominance of TH2 immune response in presence of poor CMI response as a common factor.
  • Immunological profiling to evaluate differences between immune states that are associated (such as recurrent Malaria infection) and those that are not associated (such as severe protein-energy malnutrition) with Burkitt lymphoma.
  • Prospective cohorts profiling chronology of immunological events leading to Burkitt lymphoma in children with EBV infection.
  • IMPLICATIONS OF THE HYPOTHESIS: The dysregulation of the immune response may be the missing link in our understanding of Burkitt lymphomagenesis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] IARC Sci Publ. 1985;(60):177-86 [3905588.001]
  • [Cites] P N G Med J. 1986 Mar;29(1):41-3 [3019040.001]
  • [Cites] Proc R Soc Med. 1971 Sep;64(9):909-10 [4329792.001]
  • [Cites] Clin Exp Immunol. 1984 May;56(2):371-6 [6329564.001]
  • [Cites] Prog Food Nutr Sci. 1984;8(3-4):193-228 [6396715.001]
  • [Cites] Fed Proc. 1980 Nov;39(13):3098-104 [6968692.001]
  • [Cites] Int J Cancer. 1980 Sep 15;26(3):261-6 [7287207.001]
  • [Cites] Arch Dis Child. 1995 Aug;73(2):100-4; discussion 104-5 [7574850.001]
  • [Cites] Immunol Rev. 1994 Aug;140:73-92 [7821929.001]
  • [Cites] Int J Cancer. 1994 Oct 1;59(1):20-4 [7927898.001]
  • [Cites] AIDS. 1994 Aug;8(8):1025-49 [7986399.001]
  • [Cites] AIDS. 1996 Jun;10(6):643-7 [8780819.001]
  • [Cites] Am J Pathol. 1976 Sep;84(3):599-614 [8988.001]
  • [Cites] Ann Oncol. 1997 Oct;8(10):987-94 [9402172.001]
  • [Cites] Cancer. 1998 Feb 15;82(4):766-74 [9477111.001]
  • [Cites] Hum Pathol. 1998 Nov;29(11):1285-9 [9824108.001]
  • [Cites] Cent Afr J Med. 1998 Oct;44(10):242-5 [10101432.001]
  • [Cites] N Engl J Med. 2000 Aug 17;343(7):481-92 [10944566.001]
  • [Cites] AIDS. 2000 Dec 22;14(18):2929-36 [11153674.001]
  • [Cites] Int J Cancer. 2001 Jun 1;92(5):622-7 [11340563.001]
  • [Cites] Int J Cancer. 2001 Jun 1;92(5):687-91 [11340573.001]
  • [Cites] J Gen Virol. 2001 Dec;82(Pt 12):3051-5 [11714983.001]
  • [Cites] J Natl Cancer Inst. 1976 Mar;56(3):479-83 [1255780.001]
  • [Cites] Blood. 1992 Sep 1;80(5):1289-98 [1325212.001]
  • [Cites] Ann Med Interne (Paris). 2003 Dec;154(8):523-8 [15037828.001]
  • [Cites] Nat Rev Microbiol. 2005 Feb;3(2):182-7 [15685227.001]
  • [Cites] Int J Immunopharmacol. 1992 Apr;14(3):361-6 [1618590.001]
  • [Cites] Mol Immunol. 2007 Feb;44(5):934-42 [16730063.001]
  • [Cites] Pediatr Blood Cancer. 2007 May;48(5):515-20 [16794998.001]
  • [Cites] Transplantation. 2006 Oct 27;82(8):1013-23 [17060848.001]
  • [Cites] Eur J Cancer Prev. 2007 Feb;16(1):55-61 [17220705.001]
  • [Cites] Cancer. 1991 Dec 1;68(11):2466-72 [1933784.001]
  • [Cites] Int J Cancer. 1990 Apr 15;45(4):650-3 [2323841.001]
  • [Cites] Paediatr Perinat Epidemiol. 1990 Jul;4(3):303-24 [2374749.001]
  • [Cites] Am J Epidemiol. 1989 Apr;129(4):740-52 [2923122.001]
  • [Cites] Am J Med. 1970 Mar;48(3):279-85 [4190958.001]
  • (PMID = 17509139.001).
  • [ISSN] 1750-9378
  • [Journal-full-title] Infectious agents and cancer
  • [ISO-abbreviation] Infect. Agents Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1884132
  •  go-up   go-down


27. Yone CL, Kube D, Kremsner PG, Luty AJ: Persistent Epstein-Barr viral reactivation in young African children with a history of severe Plasmodium falciparum malaria. Trans R Soc Trop Med Hyg; 2006 Jul;100(7):669-76
Genetic Alliance. consumer health - Malaria.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Persistent Epstein-Barr viral reactivation in young African children with a history of severe Plasmodium falciparum malaria.
  • Epstein-Barr virus (EBV) and Plasmodium falciparum have overlapping distributions and are thought to have causal interactions, particularly with regard to the aetiology of endemic Burkitt's lymphoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16313933.001).
  • [ISSN] 0035-9203
  • [Journal-full-title] Transactions of the Royal Society of Tropical Medicine and Hygiene
  • [ISO-abbreviation] Trans. R. Soc. Trop. Med. Hyg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimalarials; 0 / Cytokines; 0 / DNA, Viral
  •  go-up   go-down


28. Park SS, Kim JS, Tessarollo L, Owens JD, Peng L, Han SS, Tae Chung S, Torrey TA, Cheung WC, Polakiewicz RD, McNeil N, Ried T, Mushinski JF, Morse HC 3rd, Janz S: Insertion of c-Myc into Igh induces B-cell and plasma-cell neoplasms in mice. Cancer Res; 2005 Feb 15;65(4):1306-15
SciCrunch. Marmoset Gene list: Data: Gene Annotation .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The insertion of Myc(His) mimicked both the human t(8;14)(q24;q32) translocation that results in the activation of MYC in human endemic Burkitt lymphomas and the homologous mouse T(12;15) translocation that deregulates Myc in certain mouse plasmacytomas.
  • Beginning at the age of 6 months, Myc(His) transgenic mice developed B-cell and plasma neoplasms, such as IgM(+) lymphoblastic B-cell lymphomas, Bcl-6(+) diffuse large B-cell lymphomas, and CD138(+) plasmacytomas, with an overall incidence of 68% by 21 months.
  • Molecular studies of lymphoblastic B-cell lymphoma, the most prevalent neoplasm (50% of all tumors), showed that the lymphomas were clonal, overexpressed Myc(His), and exhibited the P2 to P1 promoter shift in Myc expression, a hallmark of MYC/Myc deregulation in human endemic Burkitt lymphoma and mouse plasmacytoma.
  • Only 1 (6.3%) of 16 lymphoblastic B-cell lymphomas contained a BL-typical point mutation in the amino-terminal transactivation domain of Myc(His), suggesting that most of these tumors are derived from naive, pregerminal center B cells.
  • Twelve (46%) of 26 lymphoblastic B-cell lymphomas exhibited changes in the p19(Arf)-Mdm2-p53 tumor suppressor axis, an important pathway for Myc-dependent apoptosis.
  • We conclude that Myc(His) insertion into Igh predictably induces B-cell and plasma-cell tumors in mice, providing a valuable mouse model for understanding the transformation-inducing consequences of the MYC/Myc-activating endemic Burkitt lymphoma t(8;14)/plasmacytoma T(12;15) translocation.
  • [MeSH-major] Chromosomes, Human, Pair 14 / genetics. Chromosomes, Human, Pair 8 / genetics. Genes, myc / genetics. Immunoglobulin Heavy Chains / genetics. Lymphoma, B-Cell / genetics. Plasmacytoma / genetics. Translocation, Genetic / genetics
  • [MeSH-minor] Amino Acid Sequence. Animals. B-Lymphocytes / physiology. Burkitt Lymphoma / genetics. Burkitt Lymphoma / pathology. Disease Models, Animal. Genes, Tumor Suppressor / physiology. Humans. Mice. Molecular Sequence Data. Point Mutation. Precancerous Conditions / genetics. Precancerous Conditions / pathology. Promoter Regions, Genetic. Transgenes


29. Moormann AM, Chelimo K, Sumba PO, Tisch DJ, Rochford R, Kazura JW: Exposure to holoendemic malaria results in suppression of Epstein-Barr virus-specific T cell immunosurveillance in Kenyan children. J Infect Dis; 2007 Mar 15;195(6):799-808
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Malaria and Epstein-Barr virus (EBV) infection are cofactors in the pathogenesis of endemic Burkitt lymphoma (eBL).
  • [MeSH-minor] Adolescent. Animals. Burkitt Lymphoma / epidemiology. Child. Child, Preschool. Humans. Kenya / epidemiology. Plasmodium falciparum

  • Genetic Alliance. consumer health - Malaria.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17299709.001).
  • [ISSN] 0022-1899
  • [Journal-full-title] The Journal of infectious diseases
  • [ISO-abbreviation] J. Infect. Dis.
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / K08 AI51565; United States / NCI NIH HHS / CA / R01 CA102667; United States / NIAID NIH HHS / AI / U01 AI43906
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


30. Sow M, Nkégoum B, Oyono JL, Garoua, Nzokou A: [Epidemiological and histological features of urogenital tumours in Cameroon]. Prog Urol; 2006 Feb;16(1):36-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: A total of 2,371 urogenital tumours were identified, corresponding to 520 prostatic adenocarcinomas, 1,066 cases of benign prostatic hyperplasia, 41 testicular tumours (9 seminomatous tumours, 7 non-seminomatous tumours, 18 lymphomas, 4 benign papillomas and 2 rhabdomyosarcomas of the spermatic cord), 169 bladder tumours (25 transitional cell carcinomas, 70 squamous cell carcinomas, 67 adenocarcinomas, 2 lymphomas, 1 sarcoma and 1 benign papilloma), and 136 kidney tumours (20 Wilms tumours, 87 renal cell carcinomas, 6 transitional cell carcinomas, 16 lymphomas, 2 other malignant tumours and 5 adenomas).
  • The urogenital tract can also be the site of endemic Burkitt lymphoma in this country.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16526537.001).
  • [ISSN] 1166-7087
  • [Journal-full-title] Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie
  • [ISO-abbreviation] Prog. Urol.
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


31. Chêne A, Donati D, Guerreiro-Cacais AO, Levitsky V, Chen Q, Falk KI, Orem J, Kironde F, Wahlgren M, Bejarano MT: A molecular link between malaria and Epstein-Barr virus reactivation. PLoS Pathog; 2007 Jun;3(6):e80
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although malaria and Epstein-Barr (EBV) infection are recognized cofactors in the genesis of endemic Burkitt lymphoma (BL), their relative contribution is not understood.
  • BL, the most common paediatric cancer in equatorial Africa, is a high-grade B cell lymphoma characterized by c-myc translocation.
  • Our results suggest that P. falciparum antigens such as CIDR1alpha can directly induce EBV reactivation during malaria infection that may increase the risk of BL development for children living in malaria-endemic areas.

  • Genetic Alliance. consumer health - Malaria.
  • MedlinePlus Health Information. consumer health - Malaria.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Virology. 1979 Apr 15;94(1):228-31 [220786.001]
  • [Cites] Nature. 1978 Mar 23;272(5651):373-5 [204874.001]
  • [Cites] Int J Cancer. 1984 Jan 15;33(1):27-32 [6319296.001]
  • [Cites] Trans R Soc Trop Med Hyg. 1983;77(6):879 [6665848.001]
  • [Cites] Science. 1986 Jun 20;232(4757):1554-6 [3012779.001]
  • [Cites] J Virol. 1989 Jan;63(1):445-9 [2462063.001]
  • [Cites] Trans R Soc Trop Med Hyg. 1988;82(5):657-9 [3075349.001]
  • [Cites] Adv Cancer Res. 1990;55:133-270 [2166998.001]
  • [Cites] Cell. 1994 Jan 28;76(2):263-74 [8293463.001]
  • [Cites] Int J Cancer. 1994 Jun 15;57(6):914-9 [8206684.001]
  • [Cites] Blood. 1997 Feb 1;89(3):919-28 [9028323.001]
  • [Cites] Infect Immun. 1998 Jun;66(6):2969-75 [9596774.001]
  • [Cites] J Virol. 2005 Jan;79(2):1296-307 [15613356.001]
  • [Cites] Malar J. 2004 Dec 15;3:50 [15601471.001]
  • [Cites] Nat Rev Microbiol. 2005 Feb;3(2):182-7 [15685227.001]
  • [Cites] J Infect Dis. 2005 Apr 15;191(8):1233-8 [15776368.001]
  • [Cites] Scand J Immunol. 2005 May;61(5):461-5 [15882438.001]
  • [Cites] J Infect Dis. 2006 Feb 1;193(3):422-6 [16388490.001]
  • [Cites] J Infect Dis. 2006 Apr 1;193(7):971-7 [16518759.001]
  • [Cites] J Med Microbiol. 2006 Jul;55(Pt 7):905-11 [16772418.001]
  • [Cites] J Immunol. 2006 Sep 1;177(5):3035-44 [16920940.001]
  • [Cites] J Virol. 2007 Feb;81(3):1390-400 [17108039.001]
  • [Cites] EMBO J. 2000 Jun 15;19(12):3080-9 [10856251.001]
  • [Cites] J Virol. 2000 Jul;74(14):6324-32 [10864642.001]
  • [Cites] J Exp Med. 2000 Jul 3;192(1):1-10 [10880521.001]
  • [Cites] J Virol. 2001 May;75(10):4482-9 [11312318.001]
  • [Cites] Science. 2001 Sep 14;293(5537):2098-100 [11557894.001]
  • [Cites] Immunity. 2002 May;16(5):745-54 [12049725.001]
  • [Cites] Clin Cancer Res. 2004 Feb 1;10(3):803-21 [14871955.001]
  • [Cites] FEMS Immunol Med Microbiol. 2004 May 1;41(1):9-26 [15094163.001]
  • [Cites] Infect Immun. 2004 Sep;72(9):5412-8 [15322039.001]
  • [Cites] J Natl Cancer Inst. 1969 Nov;43(5):1147-57 [5353242.001]
  • [Cites] Nat New Biol. 1973 Aug 15;244(137):214-7 [4353682.001]
  • [Cites] Clin Exp Immunol. 1983 Aug;53(2):335-44 [6349879.001]
  • (PMID = 17559303.001).
  • [ISSN] 1553-7374
  • [Journal-full-title] PLoS pathogens
  • [ISO-abbreviation] PLoS Pathog.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Protozoan; 0 / BZLF1 protein, Herpesvirus 4, Human; 0 / DNA, Viral; 0 / DNA-Binding Proteins; 0 / Protozoan Proteins; 0 / Trans-Activators; 0 / Viral Proteins; 0 / erythrocyte membrane protein 1, Plasmodium falciparum
  • [Other-IDs] NLM/ PMC1891325
  •  go-up   go-down


32. Tumwine LK, Orem J, Kerchan P, Byarugaba W, Pileri SA: EBV, HHV8 and HIV in B cell non Hodgkin lymphoma in Kampala, Uganda. Infect Agent Cancer; 2010;5:12

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EBV, HHV8 and HIV in B cell non Hodgkin lymphoma in Kampala, Uganda.
  • BACKGROUND: B cell non Hodgkin lymphomas account for the majority of lymphomas in Uganda.
  • The commonest is endemic Burkitt lymphoma, followed by diffuse large-B-cell lymphoma (DLBCL).
  • There has been an increase in incidence of malignant lymphoma since the onset of the HIV/AIDS pandemic.
  • To describe the prevalence of Epstein-Barr virus, Human Herpes virus 8 and Human Immunodeficiency Virus-1 in B cell non Hodgkin lymphoma biopsy specimens in Kampala, Uganda.2.
  • To describe the histopathology of non Hodgkin lymphoma by HIV serology test result in Kampala, Uganda METHOD: Tumour biopsies specimens from 119 patients with B cell non Hodgkin lymphoma were classified according to the WHO classification.
  • Real time and nested PCR were used for the detection of HIV.The patients from whom the 1991-2000 NHL biopsies had been taken did not have HIV serology results therefore 145 patients biopsies where serology results were available were used to describe the association of HIV with non Hodgkin lymphoma type during 2008-2009.
  • RESULTS: In this study, the majority (92%) of the Burkitt lymphomas and only 34.8% of the diffuse large B cell lymphomas were EBV positive.
  • None of the precursor B lymphoblastic lymphomas or the mantle cell lymphomas showed EBV integration in the lymphoma cells.None of the Burkitt lymphoma biopsies had HIV by PCR.
  • Of the 121 non Hodgkin B cell lymphoma patients with HIV test results, 19% had HIV.
  • However, only 1(0.04%) case of Burkitt lymphoma had HIV.
  • CONCLUSIONS: The majority of the Burkitt lymphomas and two fifths of the diffuse large B cell lymphomas had EBV.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AIDS. 1991 Jun;5(6):669-74 [1652978.001]
  • [Cites] Blood. 2009 Feb 5;113(6):1213-24 [18955561.001]
  • [Cites] Rev Epidemiol Sante Publique. 1980 Oct 30;28(3):307-21 [6258200.001]
  • [Cites] Eur J Cancer Clin Oncol. 1983 Oct;19(10):1393-404 [6315443.001]
  • [Cites] Baillieres Clin Haematol. 1995 Mar;8(1):165-99 [7663046.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Apr 1;8(4):379-85 [7882103.001]
  • [Cites] Cancer Res. 1994 Apr 15;54(8):2069-72 [8174106.001]
  • [Cites] Int J Cancer. 1993 Apr 22;54(1):26-36 [8478145.001]
  • [Cites] J Exp Med. 1996 May 1;183(5):2385-90 [8642350.001]
  • [Cites] Hum Pathol. 1997 Mar;28(3):367-74 [9042803.001]
  • [Cites] Hum Pathol. 1997 Sep;28(9):1026-33 [9308726.001]
  • [Cites] Int J Cancer. 1998 Sep 11;77(6):817-20 [9714046.001]
  • [Cites] AIDS. 1998 Oct 1;12(14):1921-5 [9792393.001]
  • [Cites] Hum Pathol. 1998 Nov;29(11):1285-9 [9824108.001]
  • [Cites] N Engl J Med. 1999 Nov 11;341(20):1520-9 [10559454.001]
  • [Cites] Br J Cancer. 2000 May;82(9):1585-92 [10789729.001]
  • [Cites] J Natl Cancer Inst. 1977 May;58(5):1191-6 [192894.001]
  • [Cites] AIDS. 2000 Dec 22;14(18):2929-36 [11153674.001]
  • [Cites] J Virol. 2001 Feb;75(4):1857-63 [11160684.001]
  • [Cites] Int J Cancer. 2003 Sep 1;106(3):388-95 [12845679.001]
  • [Cites] Int J Cancer. 2004 Jan 1;108(1):66-70 [14618617.001]
  • [Cites] Curr HIV Res. 2004 Jul;2(3):215-21 [15279585.001]
  • [Cites] Nat Rev Cancer. 2004 Oct;4(10):757-68 [15510157.001]
  • [Cites] PLoS Biol. 2005 Dec;3(12):e404 [16277553.001]
  • [Cites] J Infect Dis. 2006 Feb 1;193(3):422-6 [16388490.001]
  • [Cites] J Gen Virol. 2006 May;87(Pt 5):1047-74 [16603506.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Oct 3;103(40):14935-40 [17001014.001]
  • [Cites] Oncogene. 2007 Aug 2;26(35):5115-23 [17325665.001]
  • [Cites] J Clin Pathol. 2007 Dec;60(12):1358-64 [17873116.001]
  • [Cites] Hum Pathol. 2008 Jun;39(6):817-23 [18436278.001]
  • [Cites] J Clin Virol. 2008 Nov;43(3):255-9 [18723390.001]
  • [Cites] Semin Cancer Biol. 2009 Dec;19(6):411-20 [19897039.001]
  • [Cites] AIDS. 2010 Feb 20;24(4):479-90 [20051807.001]
  • [Cites] Hum Pathol. 2007 Feb;38(2):308-14 [17097130.001]
  • [Cites] Blood. 2008 Apr 1;111(7):3813-20 [18230756.001]
  • [Cites] BMC Infect Dis. 2008;8:111 [18706107.001]
  • [Cites] Adv Cancer Res. 1990;55:133-270 [2166998.001]
  • (PMID = 20591151.001).
  • [ISSN] 1750-9378
  • [Journal-full-title] Infectious agents and cancer
  • [ISO-abbreviation] Infect. Agents Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2907314
  •  go-up   go-down


33. Hesseling PB, Molyneux E, Kamiza S, Broadhead R: Rescue chemotherapy for patients with resistant or relapsed endemic Burkitt's lymphoma. Trans R Soc Trop Med Hyg; 2008 Jun;102(6):602-7
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rescue chemotherapy for patients with resistant or relapsed endemic Burkitt's lymphoma.
  • Patients with endemic Burkitt's lymphoma who failed primary treatment with the Malawi 2002 or 2003 Burkitt's lymphoma treatment protocols, consisting of high frequency cyclophosphamide 40 mg/kg and intrathecal methotrexate, were offered rescue chemotherapy.
  • This simple 15-day chemotherapy schedule salvaged 36% of patients and significantly increased the overall cure rate of our Burkitt's lymphoma patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / drug therapy. Salvage Therapy / methods

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18417177.001).
  • [ISSN] 0035-9203
  • [Journal-full-title] Transactions of the Royal Society of Tropical Medicine and Hygiene
  • [ISO-abbreviation] Trans. R. Soc. Trop. Med. Hyg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


34. Kanai K, Satoh Y, Saiki Y, Ohtani H, Sairenji T: Difference of Epstein-Barr virus isolates from Japanese patients and African Burkitt's lymphoma cell lines based on the sequence of latent membrane protein 1. Virus Genes; 2007 Jan;34(1):55-61
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Difference of Epstein-Barr virus isolates from Japanese patients and African Burkitt's lymphoma cell lines based on the sequence of latent membrane protein 1.
  • To characterize the genomic relationship between Japanese EBV and the EBV isolates of other countries, we analyzed the LMP1 nucleotide sequences in EBV positive cell lines and clinical specimens, including five African Burkitt's lymphoma (BL) cell lines, a Japanese BL cell line, a B-lymphoblastoid cell line, a nasopharyngeal carcinoma hybrid cell line, six gastric carcinoma tissues, two peripheral blood mononuclear cells, and a B95-8 cell line, which contained the prototype EBV genome.
  • The results indicate that the Japanese EBV isolates are greatly different from the African BL isolates but are closely related to the China 1, which is a strain of Chinese EBV isolates.
  • [MeSH-major] Burkitt Lymphoma / virology. Herpesvirus 4, Human / genetics. Viral Matrix Proteins / genetics

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16917741.001).
  • [ISSN] 0920-8569
  • [Journal-full-title] Virus genes
  • [ISO-abbreviation] Virus Genes
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / EBV-associated membrane antigen, Epstein-Barr virus; 0 / Viral Matrix Proteins
  •  go-up   go-down


35. Amusa YB, Adediran IA, Akinpelu VO, Famurewa OC, Olateju SO, Adegbehingbe BO, Komolafe EO, Faponle AF, Olasode BJ: Burkitt's lymphoma of the head and neck region in a Nigerian tertiary hospital. West Afr J Med; 2005 Apr-Jun;24(2):139-42
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Burkitt's lymphoma of the head and neck region in a Nigerian tertiary hospital.
  • BACKGROUND: Burkitt's lymphoma is endemic in Nigeria; it forms about 39% of all childhood cancers.
  • OBJECTIVE: This study is designed to look at the pattern of presentation of head and Neck Burkitt's lymphoma at a Nigerian Tertiary hospital and to evaluate current treatment modality.
  • DESIGN: It is a retrospective study of all confirmed Burkitt's lymphoma of the head and neck region seen at the Obafemi Awolowo University Teaching Hospital Ile Ife (OAUTHC) between 1986 and 2002.
  • PATIENTS AND METHODS: The medical records of all the patients with the histopathologically confirmed Burkitt's lymphoma over a 17-year period (1986-2002) were evaluated.
  • RESULTS: A total of 196 cases of Burkitt's lymphoma were seen over the period out of which 140 (71.4%) were in the head and neck region.
  • CONCLUSION: Head and neck remain the mostly affected parts in Burkitt's lymphoma in this environment.
  • [MeSH-major] Burkitt Lymphoma / diagnosis. Head and Neck Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] West Afr J Med. 2005 Jul-Sep;24(3):189. Adegbeingbe, OD [corrected to Adegbehingbe, BO]
  • (PMID = 16092315.001).
  • [ISSN] 0189-160X
  • [Journal-full-title] West African journal of medicine
  • [ISO-abbreviation] West Afr J Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Nigeria
  •  go-up   go-down


36. Klumb CE, Magluta EP, Rezende LM, Apa AG, Alonso JF, Maia RC: Retinoblastoma-related geneRb2/p130 are rarely mutated in Burkitt's lymphoma from Brazil. Am J Hematol; 2007 Mar;82(3):238-9
Genetic Alliance. consumer health - Burkitt's Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retinoblastoma-related geneRb2/p130 are rarely mutated in Burkitt's lymphoma from Brazil.
  • It has been suggested that alterations of cell cycle genes probably contribute to the pathogenesis of endemic Burkitt's lymphoma (BL) in addition to c-MYC translocation.
  • Mutations disrupting the normal nuclear localization signal of the retinoblastoma-related gene Rb2/p130 have been documented in BL cell lines and primary tumors from endemic areas.
  • [MeSH-major] Burkitt Lymphoma / genetics. Point Mutation. Retinoblastoma-Like Protein p130 / genetics

  • Genetic Alliance. consumer health - Retinoblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2006 Wiley-Liss, Inc.
  • (PMID = 16955460.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RBL2 protein, human; 0 / Retinoblastoma-Like Protein p130; 9007-49-2 / DNA
  •  go-up   go-down


37. Phillips JA, Griffin BE: Pilot study of sodium phenylbutyrate as adjuvant in cyclophosphamide-resistant endemic Burkitt's lymphoma. Trans R Soc Trop Med Hyg; 2007 Dec;101(12):1265-9
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pilot study of sodium phenylbutyrate as adjuvant in cyclophosphamide-resistant endemic Burkitt's lymphoma.
  • Burkitt's lymphoma (BL) accounts for the majority of childhood malignancies seen in sub-Saharan Africa.
  • In Malawi, cyclophosphamide (CPM), the mainstay of treatment for endemic BL, is effective in around 50% of cases.
  • It has also shown some success as adjuvant in treatment of chronic leukaemia and lymphoma.
  • We tested in African BL patients with CPM-resistant tumours, and thus unlikely to survive, the hypothesis that PB can reverse this resistance.
  • [MeSH-major] Adjuvants, Immunologic / therapeutic use. Antineoplastic Agents, Alkylating / therapeutic use. Burkitt Lymphoma / drug therapy. Cyclophosphamide / therapeutic use. Phenylbutyrates / therapeutic use

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17915270.001).
  • [ISSN] 0035-9203
  • [Journal-full-title] Transactions of the Royal Society of Tropical Medicine and Hygiene
  • [ISO-abbreviation] Trans. R. Soc. Trop. Med. Hyg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Antineoplastic Agents, Alkylating; 0 / Phenylbutyrates; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


38. Spugnini EP, Pagotto A, Zazzera F, D'Avino A, Caruso G, Citro G, Baldi A: Cutaneous T-cell lymphoma in an African hedgehog (Atelerix albiventris). In Vivo; 2008 Jan-Feb;22(1):43-5
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous T-cell lymphoma in an African hedgehog (Atelerix albiventris).
  • A three-year-old male African hedgehog was presented for a non healing crusty proliferation on the left pinna.
  • The histopathology report enabled a diagnosis of completely excised cutaneous T-cell lymphoma.
  • This report represents the first successful treatment of a cutanous T-cell lymphoma in this species and might help to plan future therapies.
  • [MeSH-major] Hedgehogs. Lymphoma, T-Cell, Cutaneous / veterinary. Skin Neoplasms / veterinary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18396780.001).
  • [ISSN] 0258-851X
  • [Journal-full-title] In vivo (Athens, Greece)
  • [ISO-abbreviation] In Vivo
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antigens, CD3; 0 / Antigens, CD79; 0 / Biomarkers, Tumor
  •  go-up   go-down


39. Harrison TM, Sikarskie J, Kitchell B, Rosenstein DS, Flaherty H, Fitzgerald SD, Kiupel M: Treatment of malignant lymphoma in an African lion (Panthera leo). J Zoo Wildl Med; 2007 Jun;38(2):333-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of malignant lymphoma in an African lion (Panthera leo).
  • A 14 yr-old male, vasectomized African lion (Panthera leo) exhibited mild weight loss despite adequate appetite.
  • On the basis of hematology and clinical pathology, malignant lymphoma with chronic lymphocytic leukemia was diagnosed.
  • Histologic examination and immunohistochemistry confirmed a small cell peripheral T-cell lymphoma.
  • The lion survived 504 days from initial diagnosis.
  • At necropsy, the only lesions consistent with lymphoma were localized epitheliotrophic infiltrates of small neoplastic T lymphocytes within the nasopharyngeal epithelium and the underlying submucosa observed on microscopic examination.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lions. Lymphoma, T-Cell, Peripheral / veterinary. Splenic Neoplasms / veterinary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17679520.001).
  • [ISSN] 1042-7260
  • [Journal-full-title] Journal of zoo and wildlife medicine : official publication of the American Association of Zoo Veterinarians
  • [ISO-abbreviation] J. Zoo Wildl. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


40. Omoti AE, Omoti CE: Ophthalmic manifestations of lymphoma. Ann Afr Med; 2007 Sep;6(3):89-93
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ophthalmic manifestations of lymphoma.
  • BACKGROUND: Ophthalmic involvement in lymphoma is a relatively rare condition that can result from a primary intraocular lymphoma or an intraocular manifestation of systemic lymphoma.
  • This report reviews the ophthalmic manifestations of lymphoma.
  • RESULTS: Almost all the structures in the orbit, adnexiae and eye can be involved in lymphoma.
  • Lymphoma of the eye and adnexiae are most frequently of B lineage.
  • Correct diagnosis thus depends on a high index of suspicion and frequently requires radiologic imaging, histologic analysis, particularly vitreous biopsy or flow cytometry, subretinal aspiration and retinal biopsy.
  • Diagnosis is often delayed and may lead to a fatal outcome.
  • Recognition of its modes of presentation facilitates early diagnosis and treatment that may improve prognosis.
  • CONCLUSIONS: It is important to review the ocular manifestations of lymphoma to assist the ophthalmologist to play a pivotal role in the prompt diagnosis and treatment of ocular lymphoma, and the haematologist/oncologist to recognize the need for a complete ophthalmic evaluation in the diagnosis, follow-up and management of lymphoma patients.
  • [MeSH-major] Eye Diseases / etiology. Lymphoma / complications

  • MedlinePlus Health Information. consumer health - Eye Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18240494.001).
  • [ISSN] 1596-3519
  • [Journal-full-title] Annals of African medicine
  • [ISO-abbreviation] Ann Afr Med
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Nigeria
  • [Number-of-references] 36
  •  go-up   go-down


41. Koffi G, Kouakou B, Ndiaye FS, Ndathz E, Sanogo I, Sangare A: [Therapeutic results and evolution of Black African patients with follicular lymphoma: Ivory Coast experience]. Bull Cancer; 2007 Oct;94(10):902-6
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Therapeutic results and evolution of Black African patients with follicular lymphoma: Ivory Coast experience].
  • [Transliterated title] Caractéristiques thérapeutiques et évolutives des lymphomes folliculaires du Noir africain: expérience de la Côte d'Ivoire.
  • We reported in this study a treatment results about 36 Africans patients with follicular lymphoma.
  • Histological, we mainly notified follicular lymphoma constituted of small cells 50%, followed by mixed follicular and large cells lymphomas with respectively 27.78 and 22.22%.
  • Indeed, the follicular lymphomas constituted by large cells and mixed cells had higher rate of complete remission with respectively 46.67% and 40% in relation with those of small cells with a higher failure rate.
  • The short survival delay time of our patients didn't permit time to observe transformation case in diffuse large cell lymphomas.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Follicular / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Bleomycin / administration & dosage. Cote d'Ivoire. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Female. Humans. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Leukemia, Lymphocytic, Chronic, B-Cell / mortality. Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / mortality. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / mortality. Lymphoma, Non-Hodgkin / pathology. Male. Middle Aged. Prednisone / administration & dosage. Retrospective Studies. Treatment Outcome. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17964984.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol; CHOP-B protocol; COP protocol 2
  •  go-up   go-down


42. Bliss A, Buriak S: Descriptive epidemiology of non-Hodgkin's lymphoma in Oklahoma: 1997-2003. J Okla State Med Assoc; 2008 Nov;101(11):262-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Descriptive epidemiology of non-Hodgkin's lymphoma in Oklahoma: 1997-2003.
  • OBJECTIVE: To describe the incidence of Non-Hodgkin's lymphoma in Oklahoma residents.
  • African Americans had a significantly lower SIR when compared to Whites: 0.72 (0.44-0.79).
  • [MeSH-major] Lymphoma, Non-Hodgkin / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19113066.001).
  • [ISSN] 0030-1876
  • [Journal-full-title] The Journal of the Oklahoma State Medical Association
  • [ISO-abbreviation] J Okla State Med Assoc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


43. Calvert JG, Slade DE, Shields SL, Jolie R, Mannan RM, Ankenbauer RG, Welch SK: CD163 expression confers susceptibility to porcine reproductive and respiratory syndrome viruses. J Virol; 2007 Jul;81(14):7371-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Transient-transfection experiments showed that full-length CD163 cDNAs from PAM, human U937 cells (histiocytic lymphoma), African green monkey kidney cells (MARC-145 and Vero), primary mouse peritoneal macrophages, and canine DH82 (histocytosis) cells encode functional virus receptors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2002 Jan 1;99(1):378-80 [11756196.001]
  • [Cites] J Leukoc Biol. 2006 Apr;79(4):837-45 [16434690.001]
  • [Cites] J Virol Methods. 2002 Jul;104(2):203-16 [12088830.001]
  • [Cites] Vet Q. 2002 Jun;24(2):95-100 [12095084.001]
  • [Cites] FEBS Lett. 2002 Aug 28;526(1-3):93-6 [12208511.001]
  • [Cites] Viral Immunol. 2002;15(4):533-47 [12513925.001]
  • [Cites] Arch Virol. 2003 Jan;148(1):177-87 [12536303.001]
  • [Cites] J Virol. 2003 Aug;77(15):8207-15 [12857889.001]
  • [Cites] Emerg Infect Dis. 2003 Aug;9(8):903-8 [12967485.001]
  • [Cites] Arch Virol. 2003 Dec;148(12):2307-23 [14648288.001]
  • [Cites] Crit Rev Immunol. 2004;24(1):1-37 [14995912.001]
  • [Cites] Vet Immunol Immunopathol. 2004 Dec 8;102(3):143-54 [15507301.001]
  • [Cites] Eur J Immunol. 1993 Sep;23(9):2320-5 [8370408.001]
  • [Cites] Arch Virol. 1993;133(3-4):477-83 [8257302.001]
  • [Cites] J Clin Microbiol. 1993 Dec;31(12):3184-9 [7508455.001]
  • [Cites] Nucleic Acids Res. 1994 Nov 11;22(22):4673-80 [7984417.001]
  • [Cites] Virus Res. 1996 Jun;42(1-2):137-47 [8806181.001]
  • [Cites] Vet Microbiol. 1997 May;56(1-2):9-19 [9228678.001]
  • [Cites] Arch Virol. 1997;142(3):629-33 [9349308.001]
  • [Cites] J Virol. 1998 Jan;72(1):380-7 [9420236.001]
  • [Cites] J Virol. 1998 May;72(5):4520-3 [9557752.001]
  • [Cites] Arch Virol. 1997;142(12):2483-97 [9672608.001]
  • [Cites] Vet Res. 2000 Jan-Feb;31(1):61-9 [10726638.001]
  • [Cites] J Immunol. 2000 Dec 1;165(11):6406-15 [11086079.001]
  • [Cites] Nature. 2001 Jan 11;409(6817):198-201 [11196644.001]
  • [Cites] Virus Genes. 2001 Mar;22(2):209-17 [11324758.001]
  • [Cites] Immunogenetics. 2001 Mar;53(2):170-7 [11345593.001]
  • [Cites] J Gen Virol. 1999 Feb;80 ( Pt 2):297-305 [10073688.001]
  • [Cites] Mol Biol Evol. 2005 Apr;22(4):1024-31 [15659555.001]
  • [Cites] J Gen Virol. 2005 May;86(Pt 5):1441-5 [15831956.001]
  • [Cites] J Am Vet Med Assoc. 2005 Aug 1;227(3):385-92 [16121604.001]
  • [Cites] Immunobiology. 2005;210(2-4):153-60 [16164022.001]
  • [Cites] Mol Biol Evol. 2005 Nov;22(11):2131-4 [16000650.001]
  • [Cites] J Virol. 2006 Jan;80(2):689-96 [16378972.001]
  • [Cites] J Virol. 2002 May;76(9):4312-20 [11932397.001]
  • (PMID = 17494075.001).
  • [ISSN] 0022-538X
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD163 antigen; 0 / DNA Primers; 0 / Membrane Glycoproteins; 0 / RNA, Messenger; 0 / Receptors, Cell Surface; 0 / Receptors, Immunologic; 0 / SIGLEC1 protein, human; 0 / Sialic Acid Binding Ig-like Lectin 1; 0 / Siglec1 protein, mouse
  • [Other-IDs] NLM/ PMC1933360
  •  go-up   go-down


44. Stefan DC, Stones D, Dippenaar A, Kidd M: Ethnicity and characteristics of Hodgkin lymphoma in children. Pediatr Blood Cancer; 2009 Feb;52(2):182-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ethnicity and characteristics of Hodgkin lymphoma in children.
  • AIM: To identify ethnic group differences in the prognostic of Hodgkin lymphoma (HL) in South African children.
  • PATIENTS AND METHODS: In order to create a larger database, cases were pooled from two South African hospitals: Tygerberg in the Western Cape and Bloemfontein Academic Complex in Free State.
  • The median age at diagnosis was 8 years 11 months.
  • [MeSH-minor] African Continental Ancestry Group. Child. Ethnic Groups. European Continental Ancestry Group. Female. Humans. Male. Prognosis. Retrospective Studies. South Africa / epidemiology. South Africa / ethnology. Survival Rate

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • [CommentIn] Pediatr Blood Cancer. 2009 Feb;52(2):153-4 [19034906.001]
  • (PMID = 18937324.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


45. Kaaya EE, Castaños-Velez E, Ekman M, Mwakigonja A, Carneiro P, Lema L, Kitinya J, Linde A, Biberfeld P: AIDS and non AIDS-related malignant lymphoma in Tanzania. Afr Health Sci; 2006 Jun;6(2):69-75
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS and non AIDS-related malignant lymphoma in Tanzania.
  • BACKGROUND: Malignant lymphoma (ML) in HIV patients, are second in frequency to Kaposi's sarcoma (AKS) as AIDS-defining tumors.
  • In Africa the frequency of AIDS-related lymphoma (ARL) is rare and the findings are controversial.
  • Kaposi's sarcoma (KS) lesions are now causally associated with KSHV/HHV-8 but whether African ARL shows this association is not clear.
  • Both retrospective and prospective lymphoma cases were classified according to the revised European-American (REAL) classification.
  • OBJECTIVES: To determine the frequency and type of AIDS and non-AIDS related malignant lymphoma in Tanzania and a possible co-association with KSHV/HHV-8 and EBV.
  • The tumors were classified as Burkitt's (6), diffuse large cell (10), precursor-B lymphoblastic (1) and Hodgkin's disease (5) from HIV positive and negative patients.
  • Ten (40%) high grade ML and three Hodgkin's lymphoma from HIV patients had HHV-8 DNA.
  • These findings were not related to age, sex or type of lymphoma.
  • There was no association of HHV-8 with the lymphoma cells.
  • [MeSH-major] Lymphoma / epidemiology. Lymphoma / pathology. Lymphoma, AIDS-Related / epidemiology
  • [MeSH-minor] Adolescent. Adult. Aged. Biopsy, Needle. Burkitt Lymphoma / epidemiology. Burkitt Lymphoma / pathology. Child. Child, Preschool. Developing Countries. Female. Herpesvirus 4, Human / isolation & purification. Herpesvirus 8, Human / isolation & purification. Hodgkin Disease / epidemiology. Hodgkin Disease / pathology. Humans. Immunohistochemistry. In Situ Hybridization. Incidence. Lymphoma, Non-Hodgkin / epidemiology. Lymphoma, Non-Hodgkin / pathology. Male. Middle Aged. Polymerase Chain Reaction. Registries. Retrospective Studies. Risk Assessment. Sarcoma, Kaposi / epidemiology. Sarcoma, Kaposi / pathology. Sarcoma, Kaposi / virology. Survival Analysis. Tanzania / epidemiology. Young Adult

  • Genetic Alliance. consumer health - AIDS-HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst Monogr. 1998;(23):79-88 [9709308.001]
  • [Cites] Br J Cancer. 1997;75(11):1704-7 [9184191.001]
  • [Cites] CA Cancer J Clin. 2005 Jul-Aug;55(4):229-41; 260-1, 264 [16020424.001]
  • [Cites] Curr HIV/AIDS Rep. 2004 Apr;1(1):5-11 [16091217.001]
  • [Cites] Br J Haematol. 2005 Sep;130(5):662-70 [16115121.001]
  • [Cites] Scand J Infect Dis. 1994;26(6):749-52 [7747100.001]
  • [Cites] Int J Cancer. 1995 May 16;61(4):574-9 [7759163.001]
  • [Cites] Blood. 1995 Aug 15;86(4):1276-80 [7632932.001]
  • [Cites] Blood. 1995 Oct 1;86(7):2708-14 [7670109.001]
  • [Cites] Lancet. 1995 Sep 23;346(8978):799-802 [7674745.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Nov 1;10(3):295-305 [7552491.001]
  • [Cites] AIDS. 2002 Mar 8;16(4):597-603 [11873003.001]
  • [Cites] J Med Virol. 2002 Oct;68(2):264-7 [12210417.001]
  • [Cites] Lancet Oncol. 2003 Feb;4(2):110-9 [12573353.001]
  • [Cites] Rev Clin Exp Hematol. 2003 Dec;7(4):375-405 [15129649.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 1985 Jun 28;34(25):373-5 [2989677.001]
  • [Cites] N Engl J Med. 1985 Dec 19;313(25):1564-71 [2999595.001]
  • [Cites] Lancet. 1991 Apr 6;337(8745):805-9 [1672911.001]
  • [Cites] J Histochem Cytochem. 1991 Jun;39(6):741-8 [1709656.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]
  • [Cites] N Engl J Med. 1995 May 4;332(18):1186-91 [7700311.001]
  • [Cites] Science. 1995 Apr 28;268(5210):582-3 [7725108.001]
  • [Cites] Nat Med. 1995 Jul;1(7):707-8 [7585156.001]
  • [Cites] Nat Med. 1995 Dec;1(12):1274-8 [7489408.001]
  • [Cites] J Virol. 1996 Jan;70(1):549-58 [8523568.001]
  • [Cites] N Engl J Med. 1996 Jan 25;334(4):272-3 [8532016.001]
  • [Cites] Arch Intern Med. 1996 Jan 22;156(2):202-4 [8546554.001]
  • [Cites] Br J Haematol. 1995 Dec;91(4):918-20 [8547139.001]
  • [Cites] Am J Clin Pathol. 1996 Feb;105(2):221-9 [8607449.001]
  • [Cites] Blood. 1996 May 1;87(9):3903-9 [8611719.001]
  • [Cites] Nat Med. 1996 Aug;2(8):918-24 [8705863.001]
  • [Cites] Nat Med. 1996 Aug;2(8):925-8 [8705864.001]
  • [Cites] J Mol Med (Berl). 1995 Dec;73(12):603-9 [8825757.001]
  • [Cites] AIDS. 1996 Aug;10(9):951-8 [8853727.001]
  • [Cites] J Virol. 1997 Mar;71(3):2505-11 [9032391.001]
  • [Cites] J Mol Diagn. 2005 Feb;7(1):17-27 [15681470.001]
  • (PMID = 16916294.001).
  • [ISSN] 1729-0503
  • [Journal-full-title] African health sciences
  • [ISO-abbreviation] Afr Health Sci
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Uganda
  • [Other-IDs] NLM/ PMC1831982
  •  go-up   go-down


46. Harif M, Barsaoui S, Benchekroun S, Bouhas R, Doumbé P, Khattab M, Ladjaj Y, Moreira C, Msefer-Alaoui F, Patte C, Rakotonirina G, Raphael M, Raquin MA, Lemerle J: Treatment of B-cell lymphoma with LMB modified protocols in Africa--report of the French-African Pediatric Oncology Group (GFAOP). Pediatr Blood Cancer; 2008 Jun;50(6):1138-42
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of B-cell lymphoma with LMB modified protocols in Africa--report of the French-African Pediatric Oncology Group (GFAOP).
  • BACKGROUND: The French African Paediatric Oncology Group (GFAOP) was set up in October 2000 to improve the quality of care of children with cancer in Africa.
  • METHODS: Patients less than 18 years with cytology or histology proven B-cell non-Hodgkin lymphoma were included.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, B-Cell / drug therapy

  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • [CommentIn] Pediatr Blood Cancer. 2008 Jun;50(6):1125-6 [18300307.001]
  • (PMID = 18213709.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 8N3DW7272P / Cyclophosphamide; YL5FZ2Y5U1 / Methotrexate; MACHO protocol
  •  go-up   go-down


47. Olowu WA, Elusiyan JB, Badejo SA, Adenowo OA: Acute renal failure in African children with Burkitt's lymphoma: a comparison of two treatment regimens. Pediatr Blood Cancer; 2006 Apr;46(4):446-53
Genetic Alliance. consumer health - Burkitt's Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute renal failure in African children with Burkitt's lymphoma: a comparison of two treatment regimens.
  • BACKGROUND: The outcome for patients presenting with acute renal failure and Burkitt lymphoma (BLARF) without dialysis is poor.
  • [MeSH-major] Acute Kidney Injury / complications. Acute Kidney Injury / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / complications. Burkitt Lymphoma / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16206217.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


48. Han YY, Dinse GE, Davis DL: Temporal and demographic patterns of non-Hodgkin's lymphoma incidence in Pennsylvania. Int J Occup Environ Health; 2010 Jan-Mar;16(1):75-84
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Temporal and demographic patterns of non-Hodgkin's lymphoma incidence in Pennsylvania.
  • Our study analyzed temporal and demographic patterns of non-Hodgkin's lymphoma (NHL) incidence in Pennsylvania and compared Pennsylvania time trends with national trends.
  • Diffuse lymphoma appeared to be the major contributor to the increases.
  • [MeSH-major] African Americans / statistics & numerical data. Demography. European Continental Ancestry Group / statistics & numerical data. Lymphoma, Non-Hodgkin / epidemiology

  • MedlinePlus Health Information. consumer health - African American Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Epidemiol. 2005 Dec 15;162(12):1162-73 [16269580.001]
  • [Cites] Health Phys. 2009 Feb;96(2):118-27 [19131733.001]
  • [Cites] J Natl Cancer Inst. 2000 Aug 2;92(15):1240-51 [10922409.001]
  • [Cites] Epidemiology. 2001 Nov;12(6):701-9 [11679800.001]
  • [Cites] J Occup Environ Med. 2002 May;44(5):469-74 [12024692.001]
  • [Cites] J Natl Cancer Inst. 2002 Oct 16;94(20):1537-45 [12381706.001]
  • [Cites] Epidemiol Rev. 2002;24(2):269-79 [12762097.001]
  • [Cites] Hematol Oncol. 2003 Jun;21(2):57-66 [12802810.001]
  • [Cites] Occup Environ Med. 2003 Sep;60(9):E11 [12937207.001]
  • [Cites] Health Phys. 2003 Dec;85(6):678-90 [14626319.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Jan;13(1):138-43 [14744745.001]
  • [Cites] Am J Epidemiol. 2004 Mar 1;159(5):454-66 [14977641.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 May;13(5):779-86 [15159310.001]
  • [Cites] J Occup Environ Med. 2004 May;46(5):479-89 [15167397.001]
  • [Cites] Oncogene. 2004 Aug 23;23(38):6524-34 [15322522.001]
  • [Cites] Biometrics. 1983 Jun;39(2):311-24 [6626659.001]
  • [Cites] N Engl J Med. 1990 Jun 7;322(23):1646-51 [2342524.001]
  • [Cites] Cancer Res. 1992 Oct 1;52(19 Suppl):5432s-5440s [1394149.001]
  • [Cites] Cancer. 1999 Mar 15;85(6):1353-60 [10189142.001]
  • [Cites] Annu Rev Public Health. 1999;20:173-209 [10352856.001]
  • [Cites] Ann Hematol. 2005 Jan;84(1):1-12 [15480663.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2):512-20 [15734980.001]
  • [Cites] JAMA. 2005 May 25;293(20):2516-25 [15914752.001]
  • [Cites] Am J Epidemiol. 2005 Nov 1;162(9):849-57 [16177143.001]
  • [Cites] Pathology. 2005 Dec;37(6):409-19 [16373224.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Apr;15(4):630-8 [16614102.001]
  • [Cites] Am J Clin Nutr. 2006 Jun;83(6):1401-10 [16762953.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Jul;15(7):1295-300 [16835326.001]
  • [Cites] AIDS. 2006 Aug 1;20(12):1645-54 [16868446.001]
  • [Cites] Eur J Cancer. 2006 Nov;42(16):2781-5 [16934973.001]
  • [Cites] Am J Epidemiol. 2006 Dec 15;164(12):1222-32 [17005624.001]
  • [Cites] Eur J Cancer. 2007 Jan;43(2):391-401 [17134891.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Mar;16(3):381-4 [17337640.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Mar;16(3):405-8 [17337643.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Mar;16(3):385-91 [17337645.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Mar;16(3):401-4 [17337646.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Mar;16(3):367-8 [17344463.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Mar;16(3):369-72 [17372232.001]
  • [Cites] Int J Cancer. 2008 May 1;122(9):2062-70 [18167059.001]
  • [Cites] Am J Epidemiol. 2008 Jun 1;167(11):1321-31 [18408225.001]
  • [Cites] Int J Cancer. 2008 Oct 1;123(7):1657-63 [18623080.001]
  • [Cites] J Natl Cancer Inst. 2008 Dec 3;100(23):1672-94 [19033571.001]
  • [Cites] Stat Med. 2000 Feb 15;19(3):335-51 [10649300.001]
  • (PMID = 20166322.001).
  • [ISSN] 1077-3525
  • [Journal-full-title] International journal of occupational and environmental health
  • [ISO-abbreviation] Int J Occup Environ Health
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / ZIA ES102265-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS202683; NLM/ PMC2895928
  •  go-up   go-down


49. Zhou Y, Wang H, Fang W, Romaguer JE, Zhang Y, Delasalle KB, Kwak L, Yi Q, Du XL, Wang M: Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004. Cancer; 2008 Aug 15;113(4):791-8
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004.
  • BACKGROUND: Mantle cell lymphoma (MCL) is a distinct subtype of B-cell non-Hodgkin's lymphoma.
  • METHODS: Patients diagnosed with MCL between 1992 and 2004 were identified from the Surveillance, Epidemiology, and End Results (SEER) Tumor registries.
  • RESULTS: Of the 87,166 patients diagnosed with non-Hodgkin's lymphoma during the 13-year period between 1992 and 2004, 2459 (2.8%) had confirmed MCL.
  • The median age at diagnosis was 68 years.
  • The incidence of MCL was higher in men (0.84 of 100,000) than in women (0.34 of 100,000) (P < .05), and was higher in Caucasians (0.61 of 100,000) than in African Americans (0.32 of 100,000).
  • [MeSH-major] Lymphoma, Mantle-Cell / epidemiology
  • [MeSH-minor] African Americans. Age Distribution. Aged. European Continental Ancestry Group. Female. Genotype. Humans. Incidence. Male. Middle Aged. Registries. SEER Program. Sex Factors. Survival Rate. Treatment Outcome. United States / epidemiology

  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2008 American Cancer Society
  • (PMID = 18615506.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / AHRQ HHS / HS / R01-HS016743
  • [Publication-type] Comparative Study; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


50. Jan A, Vora K, Sándor GK: Sporadic Burkitt's lymphoma of the jaws: the essentials of prompt life-saving referral and management. J Can Dent Assoc; 2005 Mar;71(3):165-8
Genetic Alliance. consumer health - Burkitt's Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sporadic Burkitt's lymphoma of the jaws: the essentials of prompt life-saving referral and management.
  • Burkitt's lymphoma is an undifferentiated non-Hodgkin's B-cell lymphoma.
  • Three clinical subtypes are recognized: African (endemic), American (sporadic) and HIV associated.
  • Sporadic Burkitt's lymphoma is a rare malignancy among western populations.
  • This report describes a case of sporadic Burkitt's lymphoma of the jaws with an alarmingly rapid spread associated with acute renal failure.
  • The clinical features of Burkitt's lymphoma involving the jaws include severely hypermobile, ectopically displaced and supra-erupted teeth.
  • The purpose of this case report and review of the literature is to illustrate the clinical and histopathologic features of Burkitt's lymphoma to help clinicians recognize such cases readily and facilitate prompt and potentially life-saving referral.
  • [MeSH-major] Acute Kidney Injury / complications. Burkitt Lymphoma / complications. Burkitt Lymphoma / pathology. Mandibular Neoplasms / complications. Mandibular Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15763034.001).
  • [ISSN] 1488-2159
  • [Journal-full-title] Journal (Canadian Dental Association)
  • [ISO-abbreviation] J Can Dent Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Canada
  • [Number-of-references] 16
  •  go-up   go-down


51. Othieno-Abinya NA, Abwao HO, Opiyo A, Njuguna E, Maina JM, Nyabola LO: Hodgkin's lymphoma in the 1990s: a Kenyatta National Hospital experience. East Afr Med J; 2005 Feb;82(2):59-65
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hodgkin's lymphoma in the 1990s: a Kenyatta National Hospital experience.
  • OBJECTIVE: To re-evaluate clinico-pathologic categorisation of patients with Hodgkin's lymphoma, treatments offered and their appropriateness, and outcome of this disease at Kenyatta National Hospital in the 1990s.
  • DESIGN: Retrospective survey of Hodgkin's lymphoma patients aged 13 years and above at the Kenyatta National Hospital.
  • SUBJECTS: Patients aged 13 years and above, with diagnosis of Hodgkin's lymphoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16122093.001).
  • [ISSN] 0012-835X
  • [Journal-full-title] East African medical journal
  • [ISO-abbreviation] East Afr Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Kenya
  •  go-up   go-down


52. van Lierop AC, Prescott CA: Is routine pathological examination required in South African children undergoing adenotonsillectomy? S Afr Med J; 2009 Nov;99(11):805-9
MedlinePlus Health Information. consumer health - Tonsillitis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is routine pathological examination required in South African children undergoing adenotonsillectomy?
  • OBJECTIVE: We aimed to determine the incidence of abnormal pathological findings in the tonsils and/or adenoids of children undergoing tonsillectomy and/or adenoidectomy, and the incidence of tuberculosis of the tonsils and adenoids; suggest criteria to identify children at risk for adenotonsillar tuberculosis; and investigate the association between HIV and adenotonsillar abnormality, the cost-effectiveness of routine pathological examination of adenotonsillectomy specimens, and criteria to decide which specimens to send for histological examination.
  • RESULTS: A total of 344 tonsils were analysed from 172 children (102 boys, 70 girls); 1 patient had nasopharyngeal tuberculosis, and 1 lymphoma of the tonsils; 13 (7.6%) patients had clinically asymmetrically enlarged tonsils but no significant abnormal pathological finding.
  • The average cost of detecting a clinically significant abnormality was R22 744 (R45 488 + 2 abnormalities).
  • On our evidence, routine pathological investigation for South African children does not seem to be justified.

  • MedlinePlus Health Information. consumer health - Adenoids.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20218481.001).
  • [ISSN] 0256-9574
  • [Journal-full-title] South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde
  • [ISO-abbreviation] S. Afr. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] South Africa
  •  go-up   go-down


53. Erber E, Maskarinec G, Gill JK, Park SY, Kolonel LN: Dietary patterns and the risk of non-Hodgkin lymphoma: the Multiethnic Cohort. Leuk Lymphoma; 2009 Aug;50(8):1269-75
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dietary patterns and the risk of non-Hodgkin lymphoma: the Multiethnic Cohort.
  • We examined dietary patterns and the risk of non-Hodgkin lymphoma (NHL) in the Multiethnic Cohort, which includes more than 215,000 Caucasians, African-Americans, Japanese-Americans, Native Hawaiians, and Latinos aged 45-75 at baseline.
  • However, the Vegetables pattern was inversely related to risk in Caucasian women with a hazard ratio of 0.56 (P(trend) = 0.04), and the Fat and Meat pattern was associated with a fivefold higher risk of follicular lymphoma in men (P(trend) = 0.03).

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Epidemiol. 2000 Feb 15;151(4):346-57 [10695593.001]
  • [Cites] Food Chem Toxicol. 1999 Sep-Oct;37(9-10):943-8 [10541449.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2000 May;9(5):477-85 [10815692.001]
  • [Cites] Am J Clin Nutr. 2001 Jan;73(1):1-2 [11124739.001]
  • [Cites] Nutrition. 2001 Jul-Aug;17(7-8):669-73 [11448594.001]
  • [Cites] Curr Opin Lipidol. 2002 Feb;13(1):3-9 [11790957.001]
  • [Cites] Am J Clin Nutr. 2003 Sep;78(3 Suppl):508S-513S [12936941.001]
  • [Cites] Am J Epidemiol. 2004 Mar 1;159(5):454-66 [14977641.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Oct;13(10):1665-76 [15466985.001]
  • [Cites] Fed Proc. 1975 Feb;34(2):197-201 [1116615.001]
  • [Cites] Cancer Res. 1992 Oct 1;52(19 Suppl):5492s-5495s [1394161.001]
  • [Cites] Am J Med. 1994 Sep 26;97(3A):5S-13S; discussion 22S-28S [8085584.001]
  • [Cites] Am J Clin Nutr. 1995 Dec;62(6 Suppl):1462S-1476S [7495247.001]
  • [Cites] J Am Diet Assoc. 1996 Oct;96(10):1027-39 [8841165.001]
  • [Cites] Nutr Cancer. 1997;27(3):256-60 [9101555.001]
  • [Cites] Leuk Res. 1998 May;22(5):445-52 [9652731.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2):512-20 [15734980.001]
  • [Cites] J Nutr. 2005 Apr;135(4):843-9 [15795445.001]
  • [Cites] Lancet Oncol. 2005 Jul;6(7):469-76 [15992695.001]
  • [Cites] Int J Cancer. 2006 Jun 1;118(11):2871-6 [16385566.001]
  • [Cites] Am J Clin Nutr. 2006 Jun;83(6):1401-10 [16762953.001]
  • [Cites] Leuk Lymphoma. 2006 Dec;47(12):2477-87 [17169793.001]
  • [Cites] Am J Epidemiol. 2000 Feb 15;151(4):358-70 [10695594.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Mar;16(3):392-5 [17337642.001]
  • [Cites] Int J Cancer. 2007;120 Suppl 12:1-39 [17405121.001]
  • [Cites] J Postgrad Med. 2007 Apr-Jun;53(2):139-43 [17495384.001]
  • [Cites] Blood. 2007 Jul 15;110(2):695-708 [17389762.001]
  • [Cites] Blood. 2008 Dec 15;112(13):5150-60 [18796628.001]
  • [Cites] Am J Epidemiol. 2007 Mar 15;165(6):603-10 [17220476.001]
  • [CommentIn] Leuk Lymphoma. 2009 Aug;50(8):1237-8 [19811328.001]
  • (PMID = 19811330.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R25 CA090956-05; United States / NCI NIH HHS / CA / R25 CA090956; United States / NCI NIH HHS / PC / N01-PC-35137; United States / NCI NIH HHS / PC / N01 PC035137; United States / NCI NIH HHS / CA / N01PC35137; United States / NCI NIH HHS / CA / R25 CA 90956; None / None / / N01 PC035137; United States / NCI NIH HHS / CA / R37 CA54281; United States / NCI NIH HHS / CA / CA090956-05; United States / NCI NIH HHS / CA / R37 CA054281-16; United States / NCI NIH HHS / CA / R37 CA054281
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Dietary Fats
  • [Other-IDs] NLM/ NIHMS215717; NLM/ PMC2903438
  •  go-up   go-down


54. Mwanda WO, Orem J, Remick SC, Rochford R, Whalen C, Wilson ML: Clinical characteristics of Burkitt's lymphoma from three regions in Kenya. East Afr Med J; 2005 Sep;82(9 Suppl):S135-43
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical characteristics of Burkitt's lymphoma from three regions in Kenya.
  • OBJECTIVES: To describe the clinical characteristics of Burkitt's lymphoma (BL) from three regions in Kenya at different altitudes with a view towards understanding the contribution of local environmental factors.
  • METHOD: Histologically proven cases of Burkitt's lymphoma in patients less than 16 years of age were clinically examined and investigated.
  • Tumour stage at diagnosis was: stage A--Central 21%, Coast 43% and Western 34%; stage B--Central 10%, Coast 5% and Western 10%; stage C--Central 41%, Coast 34% and Western 30%; and stage D--Central 28%, Coast 17% and Western 26%.
  • BL cases from Western province had features, intermediate between endemic and sporadic.
  • Coastal province BL cases were similar to endemic BL, while BL cases from Central province resembled more or less sporadic BL subtypes.
  • [MeSH-major] Abdominal Neoplasms / epidemiology. Altitude. Burkitt Lymphoma / epidemiology. Facial Neoplasms / epidemiology. Jaw Neoplasms / epidemiology. Topography, Medical
  • [MeSH-minor] Adolescent. Age Distribution. Child. Child, Preschool. Cross-Sectional Studies. Diagnosis, Differential. Female. Humans. Kenya / epidemiology. Lymph Nodes / physiopathology. Male. Maxilla / physiopathology. Prospective Studies. Sex Distribution. Tropical Climate

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16619689.001).
  • [ISSN] 0012-835X
  • [Journal-full-title] East African medical journal
  • [ISO-abbreviation] East Afr Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Kenya
  •  go-up   go-down


55. Stefan DC, Stones D: How much does it cost to treat children with Hodgkin lymphoma in Africa? Leuk Lymphoma; 2009 Feb;50(2):196-9
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] How much does it cost to treat children with Hodgkin lymphoma in Africa?
  • Hodgkin lymphoma (HL) is a common B-cell childhood neoplasm and it has a higher incidence in the 0-14 year age group in developing countries compared to developed countries.
  • In African countries with a small gross domestic product per capita the cost of treating HL in children may be prohibitive.
  • To determine the direct costs of treatment of HL in South Africa and to propose a more cost-effective approach to investigation and treatment for children diagnosed with HL in Africa, tumor registry data for 138 children with HL from two South African hospitals were analysed retrospectively.
  • Early diagnosis, use of less toxic protocols such as ABVD, close monitoring to prevent complications and elimination of unnecessary tests and investigations may reduce the overall cost.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Lymphoma. 2009 Feb;50(2):152-3 [19235011.001]
  • (PMID = 19197725.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


56. Metzger ML, Castellino SM, Hudson MM, Rai SN, Kaste SC, Krasin MJ, Kun LE, Pui CH, Howard SC: Effect of race on the outcome of pediatric patients with Hodgkin's lymphoma. J Clin Oncol; 2008 Mar 10;26(8):1282-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of race on the outcome of pediatric patients with Hodgkin's lymphoma.
  • We examine the effects of race on clinical outcomes among children with Hodgkin's lymphoma (HL) treated with contemporary therapy at a tertiary care children's hospital.
  • While black and white children were equally likely to have progressive disease or early relapse, black children were 3.7 times (95% CI, 1.7 to 8.0) more likely to relapse 12 months or more after diagnosis.
  • CONCLUSION: Black children with Hodgkin's lymphoma have lower event-free survival than white children, but both populations have the same 5-year overall survival.
  • [MeSH-major] African Continental Ancestry Group. European Continental Ancestry Group. Hodgkin Disease / ethnology

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18323551.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-21765; United States / NCI NIH HHS / CA / CA-36401; United States / NCI NIH HHS / CA / CA-51001; United States / NCI NIH HHS / CA / CA-60419; United States / NCI NIH HHS / CA / CA-78224; United States / NIGMS NIH HHS / GM / GM-61393
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


57. Ferry JA: Burkitt's lymphoma: clinicopathologic features and differential diagnosis. Oncologist; 2006 Apr;11(4):375-83
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Burkitt's lymphoma: clinicopathologic features and differential diagnosis.
  • Burkitt's lymphoma is a highly aggressive lymphoma identified and described in the last century by Denis Burkitt in Africa, in areas endemic for malaria.
  • Since its description in African children, it has been recognized outside areas with endemic malaria, frequently also in children as well as among individuals with an underlying immunodeficiency.
  • Since its initial designation as Burkitt's lymphoma, this type of lymphoma and lymphomas closely resembling it have received a variety of names in different classifications of lymphomas and leukemias: undifferentiated lymphoma, Burkitt's and non-Burkitt's type in the modified Rappaport Classification, malignant lymphoma, small non-cleaved cell, Burkitt's type in the Working Formulation, Burkitt's lymphoma and high-grade B-cell lymphoma, Burkitt-like in the REAL Classification, and acute lymphoblastic leukemia, L3 type in the FAB Classification.
  • With the publication of the WHO Classification of Haematopoietic and Lymphoid Tumors, the nomenclature of this lymphoma has come full circle, and it is once again known simply as Burkitt's lymphoma.
  • These efforts have led to the development of high-intensity, short-duration combination chemotherapy that has proven extremely effective for a high proportion of Burkitt's lymphoma patients.
  • The differential diagnosis of Burkitt's lymphoma is broad, and precise diagnosis based on histologic, immunophenotypic, and genetic features remains the critical first step in planning appropriate therapy.
  • [MeSH-major] Burkitt Lymphoma / pathology
  • [MeSH-minor] Diagnosis, Differential. Humans. Neoplasm Staging


58. Hosny G, Farahat N, Hainaut P: TP53 mutations in circulating free DNA from Egyptian patients with non-Hodgkin's lymphoma. Cancer Lett; 2009 Mar 18;275(2):234-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TP53 mutations in circulating free DNA from Egyptian patients with non-Hodgkin's lymphoma.
  • Mutations of P53 have been reported as common mutations in solid tumours, including non-Hodgkin lymphoma, NHL, and have been implicated in drug resistance, aggression and poor prognosis.
  • Circulating free DNA (CFDNA) has been shown to be a good source of liver tissue-derived DNA in African and Asian patients with chronic liver disease or hepatocellular carcinoma, HCC.
  • CONCLUSION: Our findings of higher DNA concentrations with some p53 mutations in CFDNA from patients with NHL that match the previous reported p53 mutations from tumour DNA may hold promises that CFDNA may serve as a convenient source of tumour-derived DNA to serve as a promising tool of a non-invasive, low-cost new strategy for earlier detection, diagnosis and follow up of the disease.
  • [MeSH-major] DNA / blood. Lymphoma, Non-Hodgkin / genetics. Mutation. Tumor Suppressor Protein p53 / genetics

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19046801.001).
  • [ISSN] 1872-7980
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / DNA Primers; 0 / Tumor Suppressor Protein p53; 9007-49-2 / DNA
  •  go-up   go-down


59. Jain M, Ascensao J, Schechter GP: Familial myeloma and monoclonal gammopathy: a report of eight African American families. Am J Hematol; 2009 Jan;84(1):34-8
MedlinePlus Health Information. consumer health - Multiple Myeloma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Familial myeloma and monoclonal gammopathy: a report of eight African American families.
  • We report here eight African American families with familial multiple myeloma and monoclonal gammopathy identified over a 30 year period.
  • The eight pedigrees had 66 members, 21 of whom had a diagnosis of cancer, including non-Hodgkin lymphoma and Hodgkin disease, or a clonal myeloproliferative disorder other than MM.
  • [MeSH-major] African Americans / genetics. Genetic Predisposition to Disease. Multiple Myeloma / genetics. Pedigree
  • [MeSH-minor] Adult. Aged. Female. Hodgkin Disease / genetics. Humans. Lymphoma, Non-Hodgkin / genetics. Male. Middle Aged. Monoclonal Gammopathy of Undetermined Significance / genetics

  • MedlinePlus Health Information. consumer health - African American Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19037864.001).
  • [ISSN] 1096-8652
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


60. Carugi A, Onnis A, Antonicelli G, Rossi B, Mannucci S, Luzzi A, Lazzi S, Bellan C, Tosi GM, Sayed S, De Falco G, Leoncini L: Geographic variation and environmental conditions as cofactors in Chlamydia psittaci association with ocular adnexal lymphomas: a comparison between Italian and African samples. Hematol Oncol; 2010 Mar;28(1):20-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Geographic variation and environmental conditions as cofactors in Chlamydia psittaci association with ocular adnexal lymphomas: a comparison between Italian and African samples.
  • A particular extra-nodal lymphoma type arises from B cells of the marginal zone (MZ) of mucosa-associated lymphoid tissue (MALT).
  • The aetiology of MZ lymphomas suggests that they are associated with chronic antigenic stimulation by microbial pathogens, among which Helicobacter pylori-associated gastric MALT lymphoma is the best studied.
  • Recently, MALT lymphomas have been described in the context of chronic conjunctivitis, which can be associated with Chlamydia spp. infection.
  • Studies from Italy showed the presence of Chlamydia psittaci in 87% of ocular adnexal lymphomas (OAL), and C. psittaci has been described in a large part of samples from Austria and Korea as well.
  • Interestingly, none of the studies up to now has been carried out in the African population, where a strong association between infectious agents and the occurrence of human neoplasms has been reported.
  • Our results showed that there was a marked variation between the two geographical areas in terms of association with C. psittaci, as 17% (5/30) of the samples from Italy were positive for C. psittaci, whereas no association with this pathogen was observed in any of the African samples (0/9), suggesting that other cofactors may determine the OAL occurrence in those areas.
  • [MeSH-major] Chlamydophila psittaci / genetics. Chlamydophila psittaci / isolation & purification. Eye Infections, Bacterial / microbiology. Eye Neoplasms / microbiology. Lymphoma, B-Cell, Marginal Zone / microbiology. Psittacosis / microbiology

  • Genetic Alliance. consumer health - Chlamydia.
  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19728399.001).
  • [ISSN] 1099-1069
  • [Journal-full-title] Hematological oncology
  • [ISO-abbreviation] Hematol Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / DNA, Bacterial
  •  go-up   go-down


61. Adeoye AO, Durosinmi MA, Adeodu OO, Kagu MB, Olateju SO, Olowu WA, Salawu IL, Kazeem OD: Ocular manifestations of Burkitt's lymphoma: experience in Ile-Ife south western Nigeria. West Afr J Med; 2007 Jan-Mar;26(1):48-52
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ocular manifestations of Burkitt's lymphoma: experience in Ile-Ife south western Nigeria.
  • BACKGROUND: Burkitt's lymphoma is the most common childhood tumour in subSaharan Africa that typically affects the jaws and abdomen.
  • OBJECTIVE: This was to evaluate the role of Burkitt's lymphoma (BL) as a cause of blindness in Nigerian children.
  • CONCLUSION: Burkitt's lymphoma is an important cause of childhood blindness in Nigeria and the orbital disease ismainly extra ocular.
  • [MeSH-major] Burkitt Lymphoma / complications. Exophthalmos / etiology

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17595992.001).
  • [ISSN] 0189-160X
  • [Journal-full-title] West African journal of medicine
  • [ISO-abbreviation] West Afr J Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Nigeria
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


62. Lukande R, Wabinga HR, Tumwine LK: Burkitt's lymphoma in Uganda: the role of immunohistochemistry in diagnosis. East Afr Med J; 2008 May;85(5):207-12
Hazardous Substances Data Bank. HEMATOXYLIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Burkitt's lymphoma in Uganda: the role of immunohistochemistry in diagnosis.
  • BACKGROUND: Haematoxylin and eosin staining has remained the standard diagnostic method for Burkitt's lymphoma.
  • Ancillary tests including immunohistochemistry, not widely available in developing countries, are important tools in verifying the diagnosis of lymphomas with equivocal morphological findings.
  • OBJECTIVE: To evaluate the reliability of haematoxylin and eosin staining in the diagnosis of Burkitt's lymphoma using immunohistochemistry as the gold standard.
  • SUBJECTS: One hundred and thirty eight formalin fixed paraffin embedded biopsies of Burkitt's lymphoma diagnosed from January 2001 to December 2005.
  • CONCLUSION: Histology using haematoxylin and eosin staining is sensitive in the diagnosis of Burkitt's lymphoma but not very specific.
  • [MeSH-major] Antigens, CD20 / analysis. Biomarkers, Tumor / analysis. Burkitt Lymphoma / diagnosis. Eosine Yellowish-(YS). Hematoxylin. Immunohistochemistry / methods. Ki-67 Antigen / analysis

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18814530.001).
  • [ISSN] 0012-835X
  • [Journal-full-title] East African medical journal
  • [ISO-abbreviation] East Afr Med J
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Kenya
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Proto-Oncogene Proteins c-bcl-2; TDQ283MPCW / Eosine Yellowish-(YS); YKM8PY2Z55 / Hematoxylin
  •  go-up   go-down


63. Martos-Díaz P, Bances-del-Castillo R, Vidal-Laso R, Mancha-de-la-Plata M, Cho-Lee GY, Naval-Gías L: Bilateral mental nerve neuropathy as the sole presenting symptom of Burkitt's Lymphoma. Med Oral Patol Oral Cir Bucal; 2009 Aug;14(8):e408-10
Genetic Alliance. consumer health - Burkitt's Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral mental nerve neuropathy as the sole presenting symptom of Burkitt's Lymphoma.
  • There are several pathologies that may cause alteration of the lower lip sensation, therefore a differential diagnosis is needed.
  • Among these pathologies, we have focused on intrabone growing tumours such as Burkitt's Lymphoma.
  • Burkitt's Lymphoma is a malignant tumour of B-Cell lymphocyte origin, classified as a Non-Hodgkin's Lymphoma.
  • Three clinical subtypes are described: endemic, sporadic and HIV associated.
  • A high incidence of Burkitt's Lymphoma has been reported in African children.
  • This report describes the case of a 29 year-old Spanish man diagnosed with Burkitt's Lymphoma, in which his first and only symptom was bilateral anaesthesia of the lower lip.
  • We have also described the clinical evolution, steps for diagnosis and treatment.
  • [MeSH-major] Burkitt Lymphoma / complications. Cranial Nerve Diseases / etiology. Mandibular Neoplasms / complications. Mandibular Nerve

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19415057.001).
  • [ISSN] 1698-6946
  • [Journal-full-title] Medicina oral, patología oral y cirugía bucal
  • [ISO-abbreviation] Med Oral Patol Oral Cir Bucal
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


64. Erber E, Lim U, Maskarinec G, Kolonel LN: Common immune-related risk factors and incident non-Hodgkin lymphoma: the multiethnic cohort. Int J Cancer; 2009 Sep 15;125(6):1440-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Common immune-related risk factors and incident non-Hodgkin lymphoma: the multiethnic cohort.
  • Severe immune dysfunction is an established risk factor of lymphoma, but the role of moderate alterations of immunity is not clear and prospective investigations are needed.
  • We examined several immune-related disorders and medications in relation to non-Hodgkin lymphoma (NHL) in the Multiethnic Cohort.
  • Over 215,000 subjects of African American, Caucasian, Japanese American, Latino and Native Hawaiian ancestry aged 45-75 years completed a questionnaire, including information on medical history, in 1993-1996.
  • Participants with a history of blood transfusion were at increased risk with HR = 1.39 (95% CI: 1.06-1.84) in men and HR = 1.22 (95% CI: 0.94-1.58) in women, especially for the diffuse large B-cell lymphoma subtype.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • MedlinePlus Health Information. consumer health - Immune System and Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2009 UICC
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Nov;15(11):2069-77 [17119030.001]
  • [Cites] Arch Intern Med. 2005 Nov 14;165(20):2337-44 [16287762.001]
  • [Cites] Lancet Oncol. 2006 Jan;7(1):27-38 [16389181.001]
  • [Cites] Cancer Detect Prev. 2006;30(1):99-101 [16495019.001]
  • [Cites] Acta Oncol. 2006;45(3):258-71 [16644568.001]
  • [Cites] Am J Epidemiol. 2006 Sep 1;164(5):497-504 [16840523.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Mar;16(3):405-8 [17337643.001]
  • [Cites] Int J Cancer. 2007;120 Suppl 12:1-39 [17405121.001]
  • [Cites] Blood. 2007 Jul 15;110(2):695-708 [17389762.001]
  • [Cites] Cancer Causes Control. 2007 Oct;18(8):821-31 [17588155.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Jan;17(1):196-203 [18187389.001]
  • [Cites] Cancer Causes Control. 2008 Mar;19(2):163-73 [18038187.001]
  • [Cites] Blood. 2008 Apr 15;111(8):4029-38 [18263783.001]
  • [Cites] Clin Trials. 2008;5(3):240-7 [18559413.001]
  • [Cites] Int J Cancer. 2008 Aug 15;123(4):888-94 [18506687.001]
  • [Cites] Am J Epidemiol. 2008 Sep 1;168(5):471-80 [18611954.001]
  • [Cites] Blood. 2008 Dec 15;112(13):5150-60 [18796628.001]
  • [Cites] Am J Epidemiol. 2000 Feb 15;151(4):346-57 [10695593.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Nov;10(11):1155-63 [11700263.001]
  • [Cites] Hepatology. 2002 Apr;35(4):974-6 [11915049.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Apr;11(4):401-7 [11927501.001]
  • [Cites] Am J Epidemiol. 2002 Apr 15;155(8):725-31 [11943690.001]
  • [Cites] Transpl Immunol. 2002 Aug;10(2-3):183-90 [12216948.001]
  • [Cites] Cancer Causes Control. 2002 Dec;13(10):965-74 [12588093.001]
  • [Cites] J Obstet Gynaecol Res. 2003 Apr;29(2):96-103 [12755530.001]
  • [Cites] Int J Cancer. 2003 Sep 20;106(5):784-8 [12866040.001]
  • [Cites] J Nutr. 2004 Jan;134(1):205-10 [14704320.001]
  • [Cites] Cancer Causes Control. 2004 May;15(4):419-28 [15141141.001]
  • [Cites] Am J Epidemiol. 2004 Aug 15;160(4):325-30 [15286017.001]
  • [Cites] Cancer. 1971 Jan;27(1):93-9 [5539630.001]
  • [Cites] Cancer Res. 1992 Oct 1;52(19 Suppl):5510s-5515s [1394165.001]
  • [Cites] Diabetes Res Clin Pract. 1994 Oct;24 Suppl:S43-52 [7859632.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Jul 1;15(3):211-22 [9257656.001]
  • [Cites] Ann Intern Med. 1997 Sep 15;127(6):423-8 [9312998.001]
  • [Cites] Int J Cancer. 1999 Jan 18;80(2):237-9 [9935205.001]
  • [Cites] Eur J Surg Suppl. 1998;(582):65-70 [10029368.001]
  • [Cites] Int J Hematol. 1999 Feb;69(2):75-80 [10071454.001]
  • [Cites] BMC Public Health. 2004 Nov 4;4:51 [15527506.001]
  • [Cites] Stat Med. 2004 Dec 30;23(24):3803-20 [15580597.001]
  • [Cites] J Natl Cancer Inst. 2005 Apr 20;97(8):587-94 [15840881.001]
  • [Cites] Cancer Causes Control. 2005 Apr;16(3):301-8 [15947882.001]
  • [Cites] Lancet Oncol. 2005 Jul;6(7):469-76 [15992695.001]
  • [Cites] Allergy. 2005 Sep;60(9):1095-7 [16076291.001]
  • [Cites] Allergy. 2005 Sep;60(9):1098-111 [16076292.001]
  • [Cites] Am J Epidemiol. 2005 Nov 15;162(10):965-74 [16192343.001]
  • [Cites] J Natl Cancer Inst. 2007 Jan 17;99(2):158-66 [17227999.001]
  • (PMID = 19444913.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / PC / N01-PC-35137; United States / NCI NIH HHS / CA / N01PC35137; United States / NCI NIH HHS / CA / R37 CA054281-17; United States / NCI NIH HHS / CA / R37CA54281; United States / NCI NIH HHS / CA / CA054281-17; United States / NCI NIH HHS / CA / R37 CA054281
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Histamine Antagonists
  • [Other-IDs] NLM/ NIHMS137658; NLM/ PMC2734966
  •  go-up   go-down


65. Dores GM, Anderson WF, Curtis RE, Landgren O, Ostroumova E, Bluhm EC, Rabkin CS, Devesa SS, Linet MS: Chronic lymphocytic leukaemia and small lymphocytic lymphoma: overview of the descriptive epidemiology. Br J Haematol; 2007 Dec;139(5):809-19
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chronic lymphocytic leukaemia and small lymphocytic lymphoma: overview of the descriptive epidemiology.
  • The 2001 World Health Organization classification scheme considers B-cell chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma (SLL) in an aggregate category (CLL/SLL) because of shared clinicopathological features.
  • We have estimated age-adjusted incidence rates (IRs) of CLL and SLL in the population-based Surveillance, Epidemiology and End Results Program in the United States to analyse patterns of CLL and SLL separately and jointly.
  • [MeSH-minor] Adult. African Continental Ancestry Group / statistics & numerical data. Age Distribution. Aged. Asian Continental Ancestry Group / statistics & numerical data. European Continental Ancestry Group / statistics & numerical data. Female. Humans. Incidence. Male. Middle Aged. SEER Program. Sex Distribution. United States / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17941952.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Intramural
  • [Publication-country] England
  •  go-up   go-down


66. Erber E, Maskarinec G, Lim U, Kolonel LN: Dietary vitamin D and risk of non-Hodgkin lymphoma: the multiethnic cohort. Br J Nutr; 2010 Feb;103(4):581-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dietary vitamin D and risk of non-Hodgkin lymphoma: the multiethnic cohort.
  • The present study explored the association between dietary vitamin D and non-Hodgkin's lymphoma (NHL) risk.
  • The multiethnic cohort (MEC) includes more than 215 000 Caucasians, African Americans, Native Hawaiians, Japanese Americans and Latinos, aged 45-75.
  • Vitamin D intake was not associated with NHL risk in the entire cohort (P(trend) = 0.72 for men and P(trend) = 0.83 for women), but significantly lowered disease risk in African American women (hazard ratio (HR) = 0.50, 95 % CI: 0.28, 0.90, P(trend) = 0.03) and was borderline protective in African American men (HR = 0.68; 95 % CI: 0.39, 1.19; P(trend) = 0.31) when the highest to the lowest tertile was compared.
  • In NHL subtype analyses, a 19, 36 and 32 % lowered risk, although not significant, was observed for diffuse large B-cell lymphoma, follicular lymphoma and small lymphocytic lymphoma/chronic lymphocytic leukemia in women, respectively.
  • High dietary intake of vitamin D did not show a protective effect against NHL within the MEC except among African Americans, possibly because vitamin D production due to sun exposure is limited in this population.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • MedlinePlus Health Information. consumer health - African American Health.
  • MedlinePlus Health Information. consumer health - Vitamin D.
  • MedlinePlus Health Information. consumer health - Vitamin D Deficiency.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Stat Med. 2004 Dec 30;23(24):3803-20 [15580597.001]
  • [Cites] Int J Cancer. 2008 Jan 1;122(1):144-54 [17708556.001]
  • [Cites] J Nutr. 2005 Oct;135(10):2478-85 [16177216.001]
  • [Cites] Mayo Clin Proc. 2006 Mar;81(3):353-73 [16529140.001]
  • [Cites] Ann Oncol. 2006 Apr;17(4):713-8 [16556850.001]
  • [Cites] Cancer Causes Control. 2006 Oct;17(8):1045-52 [16933055.001]
  • [Cites] Am J Epidemiol. 2006 Dec 15;164(12):1222-32 [17005624.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Mar;16(3):396-400 [17337644.001]
  • [Cites] Blood. 2007 Jul 15;110(2):695-708 [17389762.001]
  • [Cites] Am J Epidemiol. 2000 Feb 15;151(4):346-57 [10695593.001]
  • [Cites] Am J Epidemiol. 2000 Feb 15;151(4):358-70 [10695594.001]
  • [Cites] Am J Epidemiol. 2002 Oct 1;156(7):669-75 [12244036.001]
  • [Cites] Am J Epidemiol. 2004 Mar 1;159(5):454-66 [14977641.001]
  • [Cites] J Am Diet Assoc. 2004 Jun;104(6):980-3 [15175600.001]
  • [Cites] Am J Clin Nutr. 2004 Dec;80(6 Suppl):1678S-88S [15585788.001]
  • [Cites] Am J Clin Nutr. 2004 Dec;80(6 Suppl):1717S-20S [15585793.001]
  • [Cites] Eur J Cancer. 2007 Nov;43(16):2388-95 [17686627.001]
  • [Cites] Cancer Causes Control. 2005 Mar;16(2):83-95 [15868450.001]
  • (PMID = 19781122.001).
  • [ISSN] 1475-2662
  • [Journal-full-title] The British journal of nutrition
  • [ISO-abbreviation] Br. J. Nutr.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / PC / N01 PC035137; United States / NCI NIH HHS / CA / N01PC35137; None / None / / N01 PC035137; United States / NCI NIH HHS / CA / R37 CA54281; United States / NCI NIH HHS / CA / R37 CA054281-17; United States / NCI NIH HHS / CA / CA054281-17; United States / NCI NIH HHS / PC / N01-PC-35 137; United States / NCI NIH HHS / CA / R37 CA054281
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 1406-16-2 / Vitamin D
  • [Other-IDs] NLM/ NIHMS231119; NLM/ PMC2935689
  •  go-up   go-down


67. Hesseling P, Molyneux E, Kamiza S, Israels T, Broadhead R: Endemic Burkitt lymphoma: a 28-day treatment schedule with cyclophosphamide and intrathecal methotrexate. Ann Trop Paediatr; 2009 Mar;29(1):29-34
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endemic Burkitt lymphoma: a 28-day treatment schedule with cyclophosphamide and intrathecal methotrexate.
  • BACKGROUND: Endemic Burkitt lymphoma (eBL) is the most common childhood cancer in equatorial Africa and there is a need for affordable, effective treatment.
  • The initial diagnosis was made clinically and confirmed by fine-needle aspiration in 73%.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / drug therapy

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19222931.001).
  • [ISSN] 1465-3281
  • [Journal-full-title] Annals of tropical paediatrics
  • [ISO-abbreviation] Ann Trop Paediatr
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 8N3DW7272P / Cyclophosphamide; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


68. Smith JM, Rudser K, Gillen D, Kestenbaum B, Seliger S, Weiss N, McDonald RA, Davis CL, Stehmen-Breen C: Risk of lymphoma after renal transplantation varies with time: an analysis of the United States Renal Data System. Transplantation; 2006 Jan 27;81(2):175-80
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk of lymphoma after renal transplantation varies with time: an analysis of the United States Renal Data System.
  • BACKGROUND: Characterization of the incidence of posttransplant lymphoma over time may help guide the timing and intensity of posttransplant monitoring.
  • We analyzed the United States Renal Data System to describe the occurrence of lymphoma following renal transplantation.
  • METHODS: All end-stage renal disease patients placed on the transplant waiting list between January 1, 1990 and December 31, 1999 were considered.
  • Survival analysis was used to estimate lymphoma risk in renal transplant patients.
  • RESULTS: Of 89,260 eligible patients, a total of 556 lymphoma cases were identified with 357 in transplant patients.
  • The overall rate of posttransplant lymphoma was 33.3/10,000 person-years in transplant patients.
  • There was variation in the duration and magnitude of increased lymphoma risk by age.
  • The highest rates of lymphoma were among transplanted patients in the first 12 months, after which the rate of lymphoma decreased.
  • Among Caucasian transplant recipients less than 25 years of age, the adjusted relative risk of lymphoma ranged from 13.82 [95% CI: (3.96, 48.15)] within 6 months posttransplant to 3.46 [95% CI: (0.69, 17.44)] within months 30-36 posttransplant.
  • The risk of lymphoma differed by race, with Caucasian patients at nearly double the risk of African-Americans.
  • Gender was not associated with lymphoma incidence.
  • CONCLUSIONS: We found and quantified a time-varying relationship between renal transplant and lymphoma risk.
  • [MeSH-major] Kidney Transplantation / adverse effects. Lymphoma / etiology


69. Pulido JS, Vierkant RA, Olson JE, Abrey L, Schiff D, O'Neill BP: Racial differences in primary central nervous system lymphoma incidence and survival rates. Neuro Oncol; 2009 Jun;11(3):318-22
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Racial differences in primary central nervous system lymphoma incidence and survival rates.
  • To determine racial and ethnic differences in incidence and survival in patients with primary central nervous system lymphoma (PCNSL), NCI Surveillance, Epidemiology, and End Results (SEER) program data from 1992 to 2002 were queried.


70. Orem J, Mbidde EK, Lambert B, de Sanjose S, Weiderpass E: Burkitt's lymphoma in Africa, a review of the epidemiology and etiology. Afr Health Sci; 2007 Sep;7(3):166-75
HIV InSite. treatment guidelines - Malaria and HIV .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Burkitt's lymphoma in Africa, a review of the epidemiology and etiology.
  • Burkitt's lymphoma (BL) was first described in Eastern Africa, initially thought to be a sarcoma of the jaw.
  • Shortly it became well known that this was a distinct form of Non Hodgkin's lymphoma.
  • Evidence for a causal relationship between EBV and BL in the endemic form is fairly strong.
  • The emergence of HIV and a distinct subtype of BL in HIV infected have brought a new dimension to the disease particularly in areas where both HIV and BL are endemic.
  • [MeSH-major] Burkitt Lymphoma / epidemiology. Burkitt Lymphoma / etiology

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 1999 Nov 12;83(4):481-5 [10508483.001]
  • [Cites] Lancet. 1991 May 18;337(8751):1190 [1673740.001]
  • [Cites] Eur J Cancer. 1999 Dec;35(14):1878-85 [10711230.001]
  • [Cites] Br J Cancer. 2000 May;82(9):1585-92 [10789729.001]
  • [Cites] Int J Cancer. 2000 Nov 1;88(3):489-92 [11054682.001]
  • [Cites] AIDS. 2000 Dec 22;14(18):2929-36 [11153674.001]
  • [Cites] Int J Cancer. 2001 Jun 1;92(5):622-7 [11340563.001]
  • [Cites] Int J Cancer. 2001 Jun 1;92(5):687-91 [11340573.001]
  • [Cites] Nat Rev Cancer. 2002 Oct;2(10):764-76 [12360279.001]
  • [Cites] Br J Cancer. 2003 May 19;88(10):1566-9 [12771923.001]
  • [Cites] J Ethnopharmacol. 2003 Sep;88(1):19-44 [12902048.001]
  • [Cites] J Ethnopharmacol. 2003 Oct;88(2-3):279-86 [12963156.001]
  • [Cites] Clin Cancer Res. 2004 Feb 1;10(3):803-21 [14871955.001]
  • [Cites] Toxicon. 2004 Sep 15;44(4):417-30 [15302524.001]
  • [Cites] Cancer. 2004 Sep 15;101(6):1420-7 [15368330.001]
  • [Cites] Nat Rev Cancer. 2004 Oct;4(10):757-68 [15510157.001]
  • [Cites] Science. 1967 Sep 1;157(3792):1064-5 [6036237.001]
  • [Cites] J Virol. 1967 Aug;1(4):830-7 [4316231.001]
  • [Cites] J Natl Cancer Inst. 1971 Apr;46(4):861-71 [4324816.001]
  • [Cites] J Natl Cancer Inst. 1973 May;50(5):1163-73 [4351392.001]
  • [Cites] IARC Sci Publ. 1975;(11 Pt 2):3-16 [191375.001]
  • [Cites] Nature. 1979 Jul 19;280(5719):244-5 [221841.001]
  • [Cites] Lancet. 1981 Jul 18;2(8238):115-8 [6113482.001]
  • [Cites] Int J Cancer. 1982 Apr 15;29(4):397-400 [6282763.001]
  • [Cites] Cancer Lett. 1983 Jun;19(2):199-205 [6309363.001]
  • [Cites] Lancet. 1987 May 30;1(8544):1257-8 [2884382.001]
  • [Cites] Am J Epidemiol. 1989 Apr;129(4):740-52 [2923122.001]
  • [Cites] Trop Geogr Med. 1990 Jul;42(3):255-60 [2293434.001]
  • [Cites] Eur J Cancer. 1991;27(4):504-9 [1827731.001]
  • [Cites] Am J Pediatr Hematol Oncol. 1991 Summer;13(2):222-46 [2069232.001]
  • [Cites] Cancer. 1991 Sep 15;68(6):1356-60 [1873787.001]
  • [Cites] Cent Afr J Med. 1992 Jan;38(1):17-25 [1633615.001]
  • [Cites] Curr Opin Oncol. 1992 Oct;4(5):883-93 [1457503.001]
  • [Cites] Semin Cancer Biol. 1992 Oct;3(5):285-95 [1335792.001]
  • [Cites] Br J Cancer. 1993 Dec;68(6):1232-5 [8260378.001]
  • [Cites] Lancet. 1995 May 27;345(8961):1378-9 [7752795.001]
  • [Cites] Blood. 1996 Jun 15;87(12):5279-86 [8652843.001]
  • [Cites] IARC Monogr Eval Carcinog Risks Hum. 1997;70:1-492 [9705682.001]
  • [Cites] J Virol. 1998 Oct;72(10):8105-14 [9733851.001]
  • [Cites] Hum Pathol. 1998 Nov;29(11):1285-9 [9824108.001]
  • [Cites] Br J Surg. 1958 Nov;46(197):218-23 [13628987.001]
  • [Cites] Cancer. 1961 Mar-Apr;14:258-69 [14448554.001]
  • [Cites] Lancet Oncol. 2004 Dec;5(12):738-46 [15581545.001]
  • [Cites] Nat Rev Microbiol. 2005 Feb;3(2):182-7 [15685227.001]
  • [Cites] AIDS. 1999 Dec 24;13(18):2563-70 [10630526.001]
  • (PMID = 18052871.001).
  • [ISSN] 1729-0503
  • [Journal-full-title] African health sciences
  • [ISO-abbreviation] Afr Health Sci
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Uganda
  • [Number-of-references] 50
  • [Other-IDs] NLM/ PMC2269718
  •  go-up   go-down


71. Pereira CM, Lopes AP, Meneghini AJ, Silva GB, Monteiro MC, Botelho Tde L: Burkitt's lymphoma in a young Brazilian boy. Malays J Pathol; 2010 Jun;32(1):59-64
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Burkitt's lymphoma in a young Brazilian boy.
  • Burkitt's lymphoma is not an uncommon malignancy in the paediatric population.
  • It is a high-grade non-Hodgkin B-cell lymphoma which may present as endemic, sporadic and human immunodeficiency-associated subtypes.
  • The African, or endemic, variant usually involves the maxilla and other facial bones while head and neck manifestations in sporadic Burkitt's lymphoma are rare.
  • We described a case of oral Burkitt's lymphoma involving the right jaw in a 4-year-old boy.
  • [MeSH-major] Burkitt Lymphoma / pathology. Mandibular Neoplasms / pathology

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20614728.001).
  • [ISSN] 0126-8635
  • [Journal-full-title] The Malaysian journal of pathology
  • [ISO-abbreviation] Malays J Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Malaysia
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / Antigens, CD3; 0 / Biomarkers, Tumor; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; EC 3.4.24.11 / Neprilysin; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


72. Kagu MB, Ahmed SG, Bukar AA: Pre-treatment tumour lysis syndrome and acute renal failure in adult Nigerians with Burkitt's lymphoma: report of three cases and literature review. Afr J Med Med Sci; 2005 Dec;34(4):399-402
Genetic Alliance. consumer health - Burkitt's Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pre-treatment tumour lysis syndrome and acute renal failure in adult Nigerians with Burkitt's lymphoma: report of three cases and literature review.
  • Pre-treatment tumour lysis syndrome (pre-TTLS) is not an unusual clinical entity in high-grade lymphomas and lymphoblastic leukaemias.
  • The overall incidence and frequency is unknown and to the best of our knowledge none has been published in Nigeria involving adult females with advanced stage Burkitt's lymphoma (ASBL).
  • This paper stresses the importance of aggressive supportive management and slow introduction of cytotoxic chemotherapy in patients with a stage C and/or stage D Burkitt's lymphoma presenting with pre-TTLS.
  • [MeSH-major] Burkitt Lymphoma / complications. Renal Insufficiency / etiology. Tumor Lysis Syndrome / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16752673.001).
  • [ISSN] 0309-3913
  • [Journal-full-title] African journal of medicine and medical sciences
  • [ISO-abbreviation] Afr J Med Med Sci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Nigeria
  •  go-up   go-down


73. Lemerle J, Barsaoui S, Harif M, Hireche K, Ladjadj Y, Moreira C, Andoh J, Doumbé P, Togo B, Kam L, Rafaramino F, Patte C, Tournade MF, Raphaël M, Boccon-Gibod L, Mallon B, Raquin MA, Msefer Alaoui F: [Treatment of childhood cancer in Africa. Action of the Franco-African childhood cancer group]. Med Trop (Mars); 2007 Oct;67(5):497-504
MedlinePlus Health Information. consumer health - Cancer in Children.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of childhood cancer in Africa. Action of the Franco-African childhood cancer group].
  • [Transliterated title] Le traitement des cancers de l'enfant en Afrique. Travaux du groupe franco-africain d'oncologie pédiatrique.
  • The Franco-African Childhood Cancer Group (French acronym, GFAOP) was founded in 2000 with aim of reducing this unfavorable situation in Africa.
  • The first feasibility trials were carried out on nephroblastoma and Burkitt's lymphoma in 12 pilot units in North Africa, West Africa, and Madagascar.
  • In the first study from 2001 to 2005 we treated 306 cases of Burkitt's lymphoma using French LMB protocols adapted to the African setting and achieved a survival rate of 61%.
  • Altogether from 2001 to 2007 more than 1000 cases of nephroblastoma and Burkitt's lymphoma were treated in African hospitals by African doctors and nurses.
  • African and French doctors worked together on protocol design, trial management, and data analysis.

  • Genetic Alliance. consumer health - Childhood Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18225736.001).
  • [ISSN] 0025-682X
  • [Journal-full-title] Médecine tropicale : revue du Corps de santé colonial
  • [ISO-abbreviation] Med Trop (Mars)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


74. Lobetti RG: Lymphoma in 3 related Rottweilers from a single household. J S Afr Vet Assoc; 2009 Jun;80(2):103-5
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphoma in 3 related Rottweilers from a single household.
  • Over a period of approximately 1 year, 2 sibling Rottweilers and their dam in the same household developed stage IV and stage III lymphoma, respectively.
  • As no obvious environmental trigger could be identified in these dogs, it is speculated that an underlying genetic predisposition could have played a role in the development of lymphoma in these related dogs.
  • [MeSH-major] Antibiotics, Antineoplastic / therapeutic use. Dog Diseases / genetics. Doxorubicin / therapeutic use. Lymphoma / veterinary

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19831272.001).
  • [ISSN] 1019-9128
  • [Journal-full-title] Journal of the South African Veterinary Association
  • [ISO-abbreviation] J S Afr Vet Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] South Africa
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 80168379AG / Doxorubicin
  •  go-up   go-down


75. Bolarinwa RA, Ndakotsu MA, Oyekunle AA, Salawu L, Akinola NO, Durosinmi MA: AIDS-related lymphomas in Nigeria. Braz J Infect Dis; 2009 Oct;13(5):359-61
Genetic Alliance. consumer health - AIDS-HIV.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS-related lymphomas in Nigeria.
  • Aggressive non-Hodgkin's lymphoma (NHL), including primary central nervous system (CNS) lymphoma, lymphoblastic lymphoma and non-endemic Burkitt's lymphoma have been recognized as AIDS-defining cancers in most developed countries.
  • However, HIV/AIDS epidemics appear not to have been associated with higher incidence of lymphomas in Africa.
  • We therefore carried out this study to highlight the significance or otherwise of HIV/AIDS epidemics in the pathogenesis of lymphomas in a population of Nigerians with the disease.
  • Patients with a histological diagnosis of malignant chronic lymphoproliferative diseases {non-Hodgkin lymphoma (NHL), chronic lymphocytic leukaemia (CLL), Burkitt's lymphoma (BL) and Hodgkin lymphoma (HL)} at the Obafemi Awolowo University Teaching Hospitals' Complex, Ile-Ife from January 1993 to August 2008 were noted.
  • Those patients confirmed to be HIV/AIDS positive among the cohort with lymphomas were retrospectively studied using their clinical case notes.
  • A total of 391 patients were histologically confirmed to have lymphoma {NHL-109, (27.9%); CLL-76, (19.4%); BL-178, (45.5%) and HL-28, (7.2%)} during the study period.
  • The prevalence of AIDS-related lymphomas is 2.3% compared to 4.4% found in the general population.
  • However, it is interesting that no single case of AIDS-associated BL was seen, despite the fact that Burkitt's lymphoma is endemic in this part of the world.
  • [MeSH-major] Lymphoma, AIDS-Related / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20428636.001).
  • [ISSN] 1678-4391
  • [Journal-full-title] The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases
  • [ISO-abbreviation] Braz J Infect Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


76. Davidson A, Desai F, Hendricks M, Hartley P, Millar A, Numanoglu A, Rode H: The evolving management of Burkitt's lymphoma at Red Cross Children's Hospital. S Afr Med J; 2006 Sep;96(9 Pt 2):950-4
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The evolving management of Burkitt's lymphoma at Red Cross Children's Hospital.
  • BACKGROUND: Treatment for Burkitt's lymphoma at Red Cross Children's Hospital has evolved from the use of aggressive surgery and less intensive chemotherapy to a conservative surgical approach with more intensive chemotherapy.
  • METHODS: The study was a retrospective folder review of patients diagnosed with Burkitt's lymphoma at RCCH between 1984 and 2004.
  • RESULTS: Ninety-two children were treated for Burkitt's lymphoma at RCCH between 1984 and 2004.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Burkitt Lymphoma / drug therapy. Burkitt Lymphoma / surgery. Hospitals, County. Hospitals, Pediatric

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17077923.001).
  • [ISSN] 0256-9574
  • [Journal-full-title] South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde
  • [ISO-abbreviation] S. Afr. Med. J.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] South Africa
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


77. Huo D, Ikpatt F, Khramtsov A, Dangou JM, Nanda R, Dignam J, Zhang B, Grushko T, Zhang C, Oluwasola O, Malaka D, Malami S, Odetunde A, Adeoye AO, Iyare F, Falusi A, Perou CM, Olopade OI: Population differences in breast cancer: survey in indigenous African women reveals over-representation of triple-negative breast cancer. J Clin Oncol; 2009 Sep 20;27(27):4515-21
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Population differences in breast cancer: survey in indigenous African women reveals over-representation of triple-negative breast cancer.
  • The unclassified cases could be grouped into a bad prognosis branch, with expression of vascular endothelial growth factor, B-cell lymphoma extra-large protein, and Cyclin E, and a good prognosis branch, with expression of B-cell lymphoma protein 2 and Cyclin D1.
  • CONCLUSION: These findings underscore the urgent need for research into the etiology and treatment of the aggressive molecular subtypes that disproportionately affect young women in the African diaspora.

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Triple Negative Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Intern Med. 2006 Apr 18;144(8):541-53 [16618951.001]
  • [Cites] J Clin Oncol. 2006 Mar 20;24(9):1342-9 [16549828.001]
  • [Cites] CA Cancer J Clin. 2006 May-Jun;56(3):168-83 [16737949.001]
  • [Cites] JAMA. 2006 Jun 7;295(21):2492-502 [16757721.001]
  • [Cites] N Engl J Med. 2006 Aug 10;355(6):560-9 [16899776.001]
  • [Cites] Cancer. 2007 Jan 1;109(1):25-32 [17146782.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Mar;16(3):439-43 [17372238.001]
  • [Cites] Cancer. 2007 May 1;109(9):1721-8 [17387718.001]
  • [Cites] J Surg Res. 2007 Nov;143(1):109-18 [17950079.001]
  • [Cites] Breast. 2007 Dec;16 Suppl 2:S72-7 [17714947.001]
  • [Cites] Br J Cancer. 2008 Jan 29;98(2):277-81 [18182985.001]
  • [Cites] Breast Cancer Res Treat. 2008 May;109(1):123-39 [17578664.001]
  • [Cites] Breast Cancer Res Treat. 2008 Jul;110(1):183-8 [17674190.001]
  • [Cites] Nature. 2000 Aug 17;406(6797):747-52 [10963602.001]
  • [Cites] Breast Cancer Res Treat. 2002 Jun;74(3):199-211 [12206512.001]
  • [Cites] Cent Afr J Med. 2003 Nov-Dec;49(11-12):122-6 [15301464.001]
  • [Cites] Clin Cancer Res. 2004 Aug 15;10(16):5367-74 [15328174.001]
  • [Cites] Cancer Res. 1990 Nov 1;50(21):7057-61 [2208173.001]
  • [Cites] Histopathology. 1991 Nov;19(5):403-10 [1757079.001]
  • [Cites] Br J Surg. 1992 Aug;79(8):771-5 [1393468.001]
  • [Cites] JAMA. 1994 Sep 28;272(12):947-54 [8084062.001]
  • [Cites] Nat Med. 1998 Jul;4(7):844-7 [9662379.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8 [9843981.001]
  • [Cites] Br J Surg. 1999 May;86(5):665-8 [10361191.001]
  • [Cites] J Natl Cancer Inst. 2005 Mar 16;97(6):439-48 [15770008.001]
  • [Cites] West Afr J Med. 2005 Jul-Sep;24(3):209-13 [16276696.001]
  • [Cites] Mod Pathol. 2006 Feb;19(2):264-71 [16341146.001]
  • [Cites] J Clin Oncol. 2006 May 10;24(14):2137-50 [16682732.001]
  • (PMID = 19704069.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / NIEHS NIH HHS / ES / P50 ES012382; United States / NCI NIH HHS / CA / R01 CA089085; United States / NCI NIH HHS / CA / P50 CA125183; United States / NCI NIH HHS / CA / R01 CA089085-04; United States / NCI NIH HHS / CA / P30 CA014599; United States / NCI NIH HHS / CA / P50-CA58223-09A; United States / NCI NIH HHS / CA / P50 CA058223; United States / NCI NIH HHS / CA / CA-R01 89085-01A; United States / NCI NIH HHS / CA / CA089085-04; United States / NCI NIH HHS / CA / P50 CA125183-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone
  • [Other-IDs] NLM/ PMC2754904
  •  go-up   go-down


78. Cronin DP, Harlan LC, Clegg LX, Stevens JL, Yuan G, Davis TA: Patterns of care in a population-based random sample of patients diagnosed with non-Hodgkin's lymphoma. Hematol Oncol; 2005 Jun;23(2):73-81
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patterns of care in a population-based random sample of patients diagnosed with non-Hodgkin's lymphoma.
  • New therapies have enhanced treatment of non-Hodgkin's lymphoma (NHL), but extent of treatment use in community practice is unknown.
  • We conducted a population-based study of NHL patients diagnosed in 1999 with histologically confirmed NHL (n = 947) residing in areas covered by the Surveillance, Epidemiology, and End Results program.
  • Most patients presented with B-cell lymphoma (n = 828).
  • Hispanic and African-Americans, patients age 75 +, males, unmarried patients, or patients with B-symptoms had higher risk of death from NHL and all-cause (p < 0.01).
  • [MeSH-major] Community Health Services. Lymphoma, Non-Hodgkin / therapy. Practice Patterns, Physicians'

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16170828.001).
  • [ISSN] 0278-0232
  • [Journal-full-title] Hematological oncology
  • [ISO-abbreviation] Hematol Oncol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / PC / N01-PC-35133; United States / NCI NIH HHS / PC / N01-PC-35135; United States / NCI NIH HHS / PC / N01-PC-35136; United States / NCI NIH HHS / PC / N01-PC-35137; United States / NCI NIH HHS / PC / N01-PC-35138; United States / NCI NIH HHS / PC / N01-PC-35139; United States / NCI NIH HHS / PC / N01-PC-35141; United States / NCI NIH HHS / PC / N01-PC-35142; United States / NCI NIH HHS / PC / N01-PC-35143; United States / NCI NIH HHS / PC / N01-PC-35145
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


79. Bornkamm GW: Epstein-Barr virus and the pathogenesis of Burkitt's lymphoma: more questions than answers. Int J Cancer; 2009 Apr 15;124(8):1745-55
HIV InSite. treatment guidelines - Malaria and HIV .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epstein-Barr virus and the pathogenesis of Burkitt's lymphoma: more questions than answers.
  • Burkitt's lymphoma (BL) was first described as a clinical entity in children in Central Africa by Denis Burkitt in 1958.
  • Although epidemiological evidence clearly points to a role of the virus in the African cases, the role of EBV in the pathogenesis of BL has remained largely elusive.
  • [MeSH-major] Burkitt Lymphoma / complications. Burkitt Lymphoma / virology. Epstein-Barr Virus Infections / complications. Herpesvirus 4, Human / metabolism

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19165855.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / EBV-encoded nuclear antigen 1; 0 / Epstein-Barr Virus Nuclear Antigens; 0 / MicroRNAs
  • [Number-of-references] 171
  •  go-up   go-down


80. De Boer JD, Boellaard TN, Parkinson S, Blanchard E, Heij HA: Patient compliance in the treatment of Burkitt's lymphoma in rural Zambia: a retrospective study on 80 Burkitt's lymphoma patients in Katete, Zambia. Afr J Paediatr Surg; 2009 Jan-Jun;6(1):3-6
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patient compliance in the treatment of Burkitt's lymphoma in rural Zambia: a retrospective study on 80 Burkitt's lymphoma patients in Katete, Zambia.
  • BACKGROUND: In African settings the treatment results of Burkitt's lymphoma (BL) seem to be less favourable compared with Western settings.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Burkitt Lymphoma / drug therapy. Health Services Accessibility. Patient Compliance

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19661656.001).
  • [ISSN] 0974-5998
  • [Journal-full-title] African journal of paediatric surgery : AJPS
  • [ISO-abbreviation] Afr J Paediatr Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Nigeria
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


81. Fadiora SO, Mabayoje VO, Aderoumu AO, Adeoti ML, Olatoke SA, Oguntola AS: Generalised Burkitt's lymphoma involving both breasts--a case report. West Afr J Med; 2005 Jul-Sep;24(3):280-2
MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Generalised Burkitt's lymphoma involving both breasts--a case report.
  • BACKGROUND: Burkitt's lymphoma is a disease of children age ranging 8-10 years.
  • Lymphoma involving the breast is an unusual clinical entity, which is rarely distinguished preoperatively from other more common forms of breast cancer.
  • She was diagnosed histologically as primary breast Burkitt's lymphoma.
  • CONCLUSION: Compared with breast carcinoma, primary breast lymphoma is a rare disease but should be considered in the differential diagnosis of breast masses.
  • [MeSH-major] Breast Neoplasms / pathology. Burkitt Lymphoma / pathology. Pregnancy Complications, Neoplastic / pathology
  • [MeSH-minor] Adult. Biopsy. Diagnosis, Differential. Female. Humans. Pregnancy. Pregnancy Trimester, Third

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16276714.001).
  • [ISSN] 0189-160X
  • [Journal-full-title] West African journal of medicine
  • [ISO-abbreviation] West Afr J Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Nigeria
  •  go-up   go-down


82. Wood NH, Feller L, Raubenheimer EJ, Jadwat Y, Meyerov R, Lemmer J: Human immunodeficiency virus (HIV)-associated extranodal T cell non-Hodgkin lymphoma of the oral cavity. SADJ; 2008 Apr;63(3):158-61
MedlinePlus Health Information. consumer health - Oral Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human immunodeficiency virus (HIV)-associated extranodal T cell non-Hodgkin lymphoma of the oral cavity.
  • T cell non-Hodgkin lymphoma is characterized by uncontrolled cellular proliferation of immature malignant clones.
  • HIV-associated T cell non-Hodgkin lymphoma comprises a heterogeneous group of lymphoproliferative neoplastic entities classified according to morphological, immunological, genetic and clinical features.
  • Extranodal T cell non-Hodgkin lymphoma of the oral cavity is uncommon.
  • A case is presented with extranodal T cell non-Hodgkin lymphoma as an initial sign of HIV-infection.
  • The characteristics of HIV-associated non-Hodgkin lymphoma are discussed.
  • [MeSH-major] Lymphoma, AIDS-Related / diagnosis. Lymphoma, T-Cell / diagnosis. Mouth Neoplasms / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • Genetic Alliance. consumer health - HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18689348.001).
  • [ISSN] 1029-4864
  • [Journal-full-title] SADJ : journal of the South African Dental Association = tydskrif van die Suid-Afrikaanse Tandheelkundige Vereniging
  • [ISO-abbreviation] SADJ
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] South Africa
  •  go-up   go-down


83. Adenipekun A, Abudus-Salam A, Elumele TN: Chemotherapy in the management of advanced gastointestinal non-Hodgkin's lymphoma complicated with entero-cutaneous fistula: a case report. Afr J Med Med Sci; 2005 Jun;34(2):199-200
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy in the management of advanced gastointestinal non-Hodgkin's lymphoma complicated with entero-cutaneous fistula: a case report.
  • A case of gastrointestinal non-Hodgkin's lymphoma with entero-cutaneous fistula formation following incomplete tumor resection.
  • A case is made for conservative management of entero-cutaneous fistula complicating non- Hodgkin's lymphoma before any radical treatment is contemplated.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Gastrointestinal Neoplasms / drug therapy. Glucocorticoids / therapeutic use. Intestinal Fistula / complications. Lymphoma, Non-Hodgkin / drug therapy. Prednisolone / therapeutic use. Vincristine / therapeutic use

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Steroids.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16749349.001).
  • [ISSN] 0309-3913
  • [Journal-full-title] African journal of medicine and medical sciences
  • [ISO-abbreviation] Afr J Med Med Sci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Nigeria
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Glucocorticoids; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone
  •  go-up   go-down


84. Moore SW, Davidson A, Hadley GP, Kruger M, Poole J, Stones D, Wainwright L, Wessels G: Malignant liver tumors in South African children: a national audit. World J Surg; 2008 Jul;32(7):1389-95
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant liver tumors in South African children: a national audit.
  • This study aimed to assess recent changes in the prevalence and surgical management of liver tumors in South African children.
  • METHODS: Data were obtained from the tumor registry and pediatric oncology units in South African hospitals to audit and review the epidemiology, treatment, and outcome of malignant hepatic tumors in South African children.
  • In a further 8 patients (3%) other tumors included lymphoma and endodermal sinus tumor.

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2000 Nov 15;18(22):3819-28 [11078495.001]
  • [Cites] Pediatr Blood Cancer. 2004 Nov;43(6):706 [15390302.001]
  • [Cites] Cancer. 1985 Aug 1;56(3):575-81 [4005814.001]
  • [Cites] J Hepatol. 2004 Apr;40(4):653-9 [15030982.001]
  • [Cites] Cancer. 1999 Feb 1;85(3):562-82 [10091730.001]
  • [Cites] Int J Cancer. 2006 Jun 15;118(12):3030-44 [16404738.001]
  • [Cites] Gut. 1996;38 Suppl 2:S31-6 [8786050.001]
  • [Cites] J Pediatr Surg. 2006 Jan;41(1):e49-51 [16410090.001]
  • [Cites] Lancet. 1968 Apr 27;1(7548):921-2 [4171522.001]
  • [Cites] J Pediatr Surg. 2007 Jan;42(1):62-7; discussion 67-8 [17208542.001]
  • [Cites] Pediatr Dev Pathol. 2001 Sep-Oct;4(5):482-9 [11779051.001]
  • [Cites] Cancer. 2003 Apr 15;97(8):2006-12 [12673731.001]
  • [Cites] Rev Med Interne. 2006 Mar;27(3):227-35 [16337065.001]
  • [Cites] Med Pediatr Oncol. 2002 Aug;39(2):109-14 [12116058.001]
  • [Cites] Eur J Cancer. 1997 Jul;33(8):1243-9 [9301450.001]
  • [Cites] Cancer. 1980 Jul 15;46(2):372-9 [6248194.001]
  • [Cites] Eur J Cancer Prev. 2002 Aug;11 Suppl 2:S58-64 [12570336.001]
  • [Cites] Int J Cancer. 2007 Oct 1;121(7):1624-6 [17557292.001]
  • [Cites] Clin Liver Dis. 2000 Feb;4(1):257-68 [11232189.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2006 Jun;14(2):193-7 [16785789.001]
  • [Cites] Transplantation. 1963 Apr;1:174-80 [14010646.001]
  • [Cites] Eur J Cancer. 2005 Mar;41(5):741-8 [15763651.001]
  • [Cites] J Hepatol. 2001 Jan;34(1):178-9 [11211901.001]
  • [Cites] Pediatr Dev Pathol. 1998 Sep-Oct;1(5):438-42 [9688769.001]
  • [Cites] J Clin Oncol. 2002 Jun 15;20(12):2798-804 [12065556.001]
  • [Cites] Cancer. 2004 Aug 1;101(3):642-9 [15274079.001]
  • [Cites] Am J Surg Pathol. 2004 May;28(5):559-68 [15105642.001]
  • [Cites] J Natl Med Assoc. 2006 Dec;98(12):1934-9 [17225837.001]
  • [Cites] J Clin Oncol. 2006 Jun 1;24(16):2417-9 [16735700.001]
  • [Cites] Hepatology. 2003 Sep;38(3):560-6 [12939582.001]
  • [Cites] J Clin Epidemiol. 2003 May;56(5):487-93 [12812824.001]
  • [Cites] Anticancer Res. 1995 Nov-Dec;15(6B):2723-5 [8669853.001]
  • [Cites] N Engl J Med. 1997 Jun 26;336(26):1855-9 [9197213.001]
  • [Cites] Med Pediatr Oncol. 2002 Nov;39(5):478-83 [12228903.001]
  • [Cites] Eur J Cancer. 2006 Sep;42(13):2115-23 [16919775.001]
  • [Cites] Cancer Invest. 1992;10(6):513-22 [1384940.001]
  • [Cites] Alaska Med. 2006 Jul-Sep;48(2):30-59 [17140152.001]
  • [Cites] J Pediatr Surg. 2004 Sep;39(9):1321-7 [15359384.001]
  • [Cites] Ann Intern Med. 2001 Nov 6;135(9):796-800 [11694104.001]
  • [Cites] Mod Pathol. 1994 May;7(4):490-3 [8066077.001]
  • [Cites] Am J Epidemiol. 2006 May 1;163(9):818-28 [16510543.001]
  • [Cites] J Pediatr Surg. 1986 May;21(5):424-9 [2423669.001]
  • [Cites] Eur J Pediatr Surg. 2006 Feb;16(1):64-7 [16544232.001]
  • [Cites] Cancer. 1967 Mar;20(3):396-422 [4290059.001]
  • [Cites] Cancer. 2004 Mar 1;100(5):1070-6 [14983504.001]
  • [Cites] J Pediatr Surg. 1975 Jun;10 (3):329-37 [49416.001]
  • [Cites] N Engl J Med. 1999 Mar 11;340(10):745-50 [10072408.001]
  • [Cites] Semin Liver Dis. 1999;19(3):271-85 [10518307.001]
  • [Cites] Pediatr Radiol. 2006 Mar;36(3):173-4 [16456653.001]
  • [Cites] Toxicology. 2002 Dec 27;181-182:35-8 [12505281.001]
  • [Cites] Med Pediatr Oncol. 2002 Nov;39(5):508-9 [12228908.001]
  • [Cites] S Afr Med J. 1995 May;85(5):339 [7638675.001]
  • (PMID = 18305988.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


85. Valenzuela-Salas B, Dean-Ferrer A, Alamillos-Granados FJ: Burkitt's lymphoma: a child's case presenting in the maxilla. Clinical and radiological aspects. Med Oral Patol Oral Cir Bucal; 2010 May;15(3):e479-82
Genetic Alliance. consumer health - Burkitt's Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Burkitt's lymphoma: a child's case presenting in the maxilla. Clinical and radiological aspects.
  • Burkitt's lymphoma (BL) is a neoplasm which, despite its very aggressive behaviour is potentially curable.
  • BL belongs to the non-Hodgkin lymphomas group, and is the first human tumour undoubtedly related to a viral origin (Epstein-Barr virus).
  • Two main clinical subtypes are recognized: endemic or African type, and sporadic type; HIV associated BL constitutes a third type.
  • Although common in endemic BL, maxillary involvement is rare in sporadic cases.
  • This, together with the clinical lack of specificity associated to this location, makes diagnosis difficult.
  • [MeSH-major] Burkitt Lymphoma / diagnosis. Maxillary Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20038882.001).
  • [ISSN] 1698-6946
  • [Journal-full-title] Medicina oral, patología oral y cirugía bucal
  • [ISO-abbreviation] Med Oral Patol Oral Cir Bucal
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


86. Omoregie FO, Saheeb BD, Onasanya PO: Periradicular burkitt's lymphoma: a report of 2 cases from Nigeria and review of the literature. Afr J Med Med Sci; 2008 Sep;37(3):279-83
Genetic Alliance. consumer health - Burkitt's Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Periradicular burkitt's lymphoma: a report of 2 cases from Nigeria and review of the literature.
  • This article reports two cases of periradicular Burkitt's lymphoma from Nigeria, to emphasize the difficulties in differentiating the early lesion from other periradicular lesions with similar clinical and radiological findings Case 1, is a 4-year-old boy who presented with a one-month history of a painless, hard, posterior mandibular swelling (right), which was causing loosening and displacement of deciduous teeth (84 and 85).
  • Histopathological examination of periradicular tissues from extracted tooth (85), confirmed the diagnosis of early periradicular B urkitt's lymphoma.
  • Incisional biopsy of the oral lesion at the region of exfoliated left first mandibular molar (36) was useful for histopathological diagnosis of early Burkitt's lymphoma of the jaw.
  • In the face of limited diagnostic tools such as clinico-radiological assessment, cytology or incisional biopsy for incipient periradicular lesions, a high index of suspicion of Burkitt's lymphoma of the jaw may be helpful in early diagnosis and treatment of a lesion, presenting in a child as periradicular radiolucency or mixed radiolucency and radiopacity, with associated loosening and displacement of teeth.
  • [MeSH-major] Burkitt Lymphoma / pathology. Jaw Neoplasms / pathology
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Biopsy. Child. Child, Preschool. Diagnosis, Differential. Fatal Outcome. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18982822.001).
  • [ISSN] 0309-3913
  • [Journal-full-title] African journal of medicine and medical sciences
  • [ISO-abbreviation] Afr J Med Med Sci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Nigeria
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


87. Maskarinec G, Erber E, Gill J, Cozen W, Kolonel LN: Overweight and obesity at different times in life as risk factors for non-Hodgkin's lymphoma: the multiethnic cohort. Cancer Epidemiol Biomarkers Prev; 2008 Jan;17(1):196-203
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overweight and obesity at different times in life as risk factors for non-Hodgkin's lymphoma: the multiethnic cohort.
  • Obesity may increase the risk for non-Hodgkin's lymphoma (NHL) through an inflammatory pathway.
  • We explored the relation of NHL with body size at different times in life within the Multiethnic Cohort that includes African Americans, Caucasians, Japanese, Latinos, and Native Hawaiians.
  • [MeSH-major] Leukemia, Lymphocytic, Chronic, B-Cell / etiology. Lymphoma, B-Cell / etiology. Lymphoma, Follicular / etiology. Lymphoma, Large B-Cell, Diffuse / etiology. Lymphoma, T-Cell / etiology. Obesity / complications

  • Genetic Alliance. consumer health - Obesity.
  • MedlinePlus Health Information. consumer health - Obesity.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18187389.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R25 CA 90956; United States / NCI NIH HHS / CA / R37 CA 54281
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


88. Balogun TM, Omodele FO, Olaiya MA: Primary lymphoma of the testis in remission for more than ten years: a case report. West Afr J Med; 2009 Nov-Dec;28(6):388-90
MedlinePlus Health Information. consumer health - Testicular Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary lymphoma of the testis in remission for more than ten years: a case report.
  • BACKGROUND: Primary testicular lymphoma is a unique, rare and aggressive extra nodal non-Hodgkins Lymphoma (NHL).
  • It is the most common testicular tumour in males between 60 and 80 years old OBJECTIVE: To report a case of primary testicular lymphoma in a young man who has done very well on surgery and chemotherapy.
  • A working diagnosis of right hydrocele with differential diagnosis of lymphangioma was made.
  • CONCLUSION: Primary testicular lymphoma is a rare and unique neoplasm of the testis and is most commonly seen in men over the age of 60, but should be considered in the differential diagnosis of testicular tumours in younger age groups.
  • [MeSH-major] Lymphoma, Non-Hodgkin / pathology. Testicular Diseases / pathology. Testicular Neoplasms / pathology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Diagnosis, Differential. Humans. Male. Orchiectomy. Remission Induction. Spermatic Cord / pathology. Treatment Outcome

  • Genetic Alliance. consumer health - TEN.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20486099.001).
  • [ISSN] 0189-160X
  • [Journal-full-title] West African journal of medicine
  • [ISO-abbreviation] West Afr J Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Nigeria
  •  go-up   go-down


89. Dippenaar A, Wessels G, Hesseling PB: Improved outcome in South African children of mixed ethnicity treated for all. Pediatr Hematol Oncol; 2006 Jun;23(4):329-38

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improved outcome in South African children of mixed ethnicity treated for all.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / ethnology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16621775.001).
  • [ISSN] 1521-0669
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Hemoglobins
  •  go-up   go-down


90. Adhvaryu MR, Reddy N, Parabia MH: Anti-tumor activity of four Ayurvedic herbs in Dalton lymphoma ascites bearing mice and their short-term in vitro cytotoxicity on DLA-cell-line. Afr J Tradit Complement Altern Med; 2008 Jun 18;5(4):409-18

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anti-tumor activity of four Ayurvedic herbs in Dalton lymphoma ascites bearing mice and their short-term in vitro cytotoxicity on DLA-cell-line.
  • Curcuma longa L., Ocimum sanctum L., Tinospora cordifolia (Wild) Miers ex Hook.f & Thomas and Zizyphus mauritiana Lam. were evaluated using Dalton Lymphoma ascites (DLA) tumor model in Swiss Albino mice.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochem Int. 1992 Dec;28(4):735-44 [1482409.001]
  • [Cites] World J Gastroenterol. 2007 Jun 21;13(23):3199-205 [17589898.001]
  • [Cites] J Ethnopharmacol. 1986 Nov;18(2):133-41 [3560991.001]
  • [Cites] Indian J Exp Biol. 1995 Mar;33(3):205-8 [7601491.001]
  • [Cites] Planta Med. 1994 Apr;60(2):106-9 [8202557.001]
  • [Cites] Cancer. 1995 Sep 1;76(5):743-9 [8625175.001]
  • [Cites] J Ethnopharmacol. 1997 Oct;58(2):89-95 [9406896.001]
  • [Cites] Cancer Res. 1998 Jun 1;58(11):2323-7 [9622066.001]
  • [Cites] Pharmacol Res. 1998 Aug;38(2):107-10 [9721597.001]
  • [Cites] Oral Oncol. 1999 Jan;35(1):112-9 [10211319.001]
  • [Cites] Phytother Res. 1999 Jun;13(4):275-91 [10404532.001]
  • [Cites] J Ethnopharmacol. 2000 Nov;73(1-2):81-5 [11025142.001]
  • [Cites] J Ethnopharmacol. 2000 Dec;73(3):461-70 [11091000.001]
  • [Cites] Anticancer Res. 2003 Jan-Feb;23(1A):363-98 [12680238.001]
  • [Cites] Planta Med. 2003 Aug;69(8):692-5 [14531016.001]
  • [Cites] J Ethnopharmacol. 2004 Jan;90(1):155-60 [14698524.001]
  • [Cites] J Pharmacol Sci. 2004 Feb;94(2):177-84 [14978356.001]
  • [Cites] Biol Pharm Bull. 2004 Nov;27(11):1883-6 [15516743.001]
  • [Cites] Pharmacol Res. 2005 Jan;51(1):19-30 [15519531.001]
  • [Cites] Pharmacol Biochem Behav. 2006 Jan;83(1):67-75 [16427690.001]
  • [Cites] Indian J Exp Biol. 1990 Nov;28(11):1008-11 [2283166.001]
  • (PMID = 20161965.001).
  • [ISSN] 2505-0044
  • [Journal-full-title] African journal of traditional, complementary, and alternative medicines : AJTCAM
  • [ISO-abbreviation] Afr J Tradit Complement Altern Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Nigeria
  • [Other-IDs] NLM/ PMC2816583
  • [Keywords] NOTNLM ; Anti-tumor activity / Curcuma longa / Cytotoxicity / DLA cell line / Ocimum sanctum / Tinospora cordifolia / Zizyphus mauritiana
  •  go-up   go-down


91. Macharia WM: Outcome and haemato-toxicity of two chemotherapy regimens for childhood non-Hodgkin's lymphoma in a Kenyan hospital. East Afr Med J; 2009 Dec;86(12 Suppl):S34-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome and haemato-toxicity of two chemotherapy regimens for childhood non-Hodgkin's lymphoma in a Kenyan hospital.
  • OBJECTIVE: To evaluate effectiveness and toxicity of two treatment protocols for Non-Hodgkin's lymphoma (NHL).
  • SUBJECTS: Children < or =15 years with diagnosis of non-Hodgkin's Lymphoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy

  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21591507.001).
  • [ISSN] 0012-835X
  • [Journal-full-title] East African medical journal
  • [ISO-abbreviation] East Afr Med J
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Kenya
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; E7WED276I5 / 6-Mercaptopurine; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


92. Tageja N, Mohammad M, Bentley G, Bishop C: Adult T-Cell Leukemia/Lymphoma with CLL-Like Morphology-A Case Report. Case Rep Med; 2010;2010:729790

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult T-Cell Leukemia/Lymphoma with CLL-Like Morphology-A Case Report.
  • Adult T-cell Leukemia/Lymphoma (ATL) is rarely seen in the U.S. and Europe, usually limited to African Americans from the southeastern U.S. and immigrants from HTLV-1 endemic areas.
  • Reaching an accurate and timely diagnosis of ATL in such nonendemic areas can be challenging, owing to limited exposure, diverse manifestations, and varying cell morphology.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Haematol. 1994 Feb;86(2):383-5 [8199030.001]
  • [Cites] Br J Haematol. 1999 May;105(2):369-75 [10233406.001]
  • [Cites] J Clin Pathol. 2007 Dec;60(12):1373-7 [18042693.001]
  • [Cites] Leuk Lymphoma. 1993 Dec;12(1-2):123-30 [8161929.001]
  • [Cites] Br J Haematol. 1991 Nov;79(3):428-37 [1751370.001]
  • [Cites] J Clin Pathol. 1989 Jun;42(6):567-84 [2738163.001]
  • [Cites] Eur J Haematol. 2008 Mar;80(3):185-96 [18081707.001]
  • (PMID = 20368783.001).
  • [ISSN] 1687-9635
  • [Journal-full-title] Case reports in medicine
  • [ISO-abbreviation] Case Rep Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2846349
  •  go-up   go-down


93. Metzger ML, Hudson MM, Somes GW, Shorr RI, Li CS, Krasin MJ, Shelso J, Pui CH, Howard SC: White race as a risk factor for hypothyroidism after treatment for pediatric Hodgkin's lymphoma. J Clin Oncol; 2006 Apr 1;24(10):1516-21
Hazardous Substances Data Bank. LEVOTHYROXINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] White race as a risk factor for hypothyroidism after treatment for pediatric Hodgkin's lymphoma.
  • PURPOSE: Hypothyroidism frequently occurs after treatment for pediatric Hodgkin's lymphoma, but race has not been investigated as a risk factor for this delayed toxicity.
  • The aim of this study was to determine whether race is an independent risk factor for hypothyroidism in survivors of pediatric Hodgkin's lymphoma.
  • PATIENTS AND METHODS: To identify differences between black and white patients in the development of hypothyroidism after treatment for Hodgkin's lymphoma, we conducted a retrospective study of consecutively treated pediatric patients with newly diagnosed Hodgkin's lymphoma treated at St Jude Children's Research Hospital (Memphis, TN) from January 1980 through December 2002.
  • Hypothyroidism developed in 196 (43%) of 461 patients after a median of 2.9 years (range, 0.7 to 11.3 years) after diagnosis of Hodgkin's lymphoma.
  • CONCLUSION: White patients have a higher risk of hypothyroidism after neck irradiation for pediatric Hodgkin's lymphoma than black patients.
  • [MeSH-major] African Continental Ancestry Group. European Continental Ancestry Group. Hodgkin Disease / radiotherapy. Hypothyroidism / etiology. Neck / radiation effects

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Hypothyroidism.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16575001.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30-CA21765; United States / NCI NIH HHS / CA / R01-CA600419
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] Q51BO43MG4 / Thyroxine
  •  go-up   go-down


94. Ugar DA, Bozkaya S, Karaca I, Tokman B, Pinarli FG: Childhood craniofacial Burkitt's lymphoma presenting as maxillary swelling: report of a case and review of literature. J Dent Child (Chic); 2006 Jan-Apr;73(1):45-50
Genetic Alliance. consumer health - Burkitt's Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Childhood craniofacial Burkitt's lymphoma presenting as maxillary swelling: report of a case and review of literature.
  • Burkitt's lymphoma (BL) is an undifferentiated malignant lymphoma comprising of uniformly primitive lymphoreticular cells.
  • African type BL usually occurs in the jaws of young children.
  • BL is found most commonly in childhood, with a peak incidence in African cases at 5 to 8 years old and in American cases at 10 to 12 years old.
  • BL is the most rapidly growing neoplasm requiring immediate diagnosis and treatment; however, it is extremely sensitive to chemotherapy.
  • In this report, a case of BL that was initially misdiagnosed as an acute dental abscess is presented and the role of the dentist in the diagnosis and treatment of these patients is emphasized.
  • [MeSH-major] Burkitt Lymphoma / diagnosis. Maxillary Diseases / diagnosis. Maxillary Sinus Neoplasms / diagnosis
  • [MeSH-minor] Abscess / diagnosis. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Diagnosis, Differential. Focal Infection, Dental / diagnosis. Humans. Male. Radiography, Panoramic. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16734314.001).
  • [ISSN] 1551-8949
  • [Journal-full-title] Journal of dentistry for children (Chicago, Ill.)
  • [ISO-abbreviation] J Dent Child (Chic)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 16
  •  go-up   go-down


95. Boulanger E, Afonso PV, Yahiaoui Y, Adle-Biassette H, Gabarre J, Agbalika F: Human herpesvirus-8 (HHV-8)-associated primary effusion lymphoma in two renal transplant recipients receiving rapamycin. Am J Transplant; 2008 Mar;8(3):707-10
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human herpesvirus-8 (HHV-8)-associated primary effusion lymphoma in two renal transplant recipients receiving rapamycin.
  • The Akt/mammalian target of rapamycin (mTOR) signaling cascade has been demonstrated to be constitutively activated in several malignancies, including Kaposi sarcoma (KS) and human herpesvirus-8 (HHV-8)-associated primary effusion lymphoma (PEL).
  • In the present report, we describe the cases of two HIV-1-negative males of African origin who underwent renal transplantation and developed PEL while receiving rapamycin as immunosuppressive treatment.
  • [MeSH-major] Herpesviridae Infections / drug therapy. Herpesvirus 8, Human. Immunosuppressive Agents / therapeutic use. Kidney Transplantation. Lymphoma, Primary Effusion / drug therapy. Sirolimus / therapeutic use

  • Genetic Alliance. consumer health - Primary effusion lymphoma.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • Hazardous Substances Data Bank. SIROLIMUS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18261181.001).
  • [ISSN] 1600-6143
  • [Journal-full-title] American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
  • [ISO-abbreviation] Am. J. Transplant.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


96. Berrios-Rivera JP, Fang S, Cabanillas ME, Cabanillas F, Lu H, Du XL: Variations in chemotherapy and radiation therapy in a large nationwide and community-based cohort of elderly patients with non-Hodgkin lymphoma. Am J Clin Oncol; 2007 Apr;30(2):163-71
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Variations in chemotherapy and radiation therapy in a large nationwide and community-based cohort of elderly patients with non-Hodgkin lymphoma.
  • OBJECTIVE: The objective of this study was to determine the variations in the use of chemotherapy and radiation therapy in a large nationwide and population-based cohort of older patients with non-Hodgkin lymphoma (NHL).
  • METHODS: We studied a retrospective cohort of 13,570 patients diagnosed with incident NHL at age > or =65 in 1992 through 1999 identified from the Surveillance, Epidemiology and End Results-Medicare-linked database.
  • RESULTS: Of 13,570 patients with NHL, 52% received chemotherapy within 6 months of diagnosis.
  • In multivariate analysis, there was no significant association between the receipt of chemotherapy and gender or year of diagnosis, but blacks had statistically significant lower odds of receiving chemotherapy than white patients (odds ratio = 0.66, 95% confidence interval: 0.55-0.80).
  • The percentages of patients receiving radiation therapy, chemotherapy, or both were 11%, 39%, and 13%, respectively; 37% of patients with NHL did not receive any of these treatments within 6 months of diagnosis.
  • [MeSH-major] Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / radiotherapy
  • [MeSH-minor] African Continental Ancestry Group. Aged. Aged, 80 and over. Cohort Studies. Combined Modality Therapy. European Continental Ancestry Group. Female. Geography. Humans. Male. Medicare. Neoplasm Staging. Registries. Retrospective Studies. United States

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17414466.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


97. Wang M, Burau KD, Fang S, Wang H, Du XL: Ethnic variations in diagnosis, treatment, socioeconomic status, and survival in a large population-based cohort of elderly patients with non-Hodgkin lymphoma. Cancer; 2008 Dec 1;113(11):3231-41
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ethnic variations in diagnosis, treatment, socioeconomic status, and survival in a large population-based cohort of elderly patients with non-Hodgkin lymphoma.
  • BACKGROUND: There is a lack of research on ethnic disparities in survival among patients with non-Hodgkin lymphoma (NHL), although these disparities have been documented for patients with many other tumors.
  • METHODS: A retrospective cohort of 13,321 patients diagnosed with incident NHL at age > or = 65 years from 1992 to 1999 were identified from the Surveillance, Epidemiology, and End Results (SEER)-Medicare linked database with 11 years of follow-up.
  • Of these patients, 11,868 were Caucasians, 533 were African Americans, and 920 were other ethnicities.
  • RESULTS: A larger proportion (72.2%) of African Americans were in the poorest quartile of socioeconomic status as measured by the poverty level compared with 21.8% of Caucasians, and 43.2% of African Americans received chemotherapy compared with 52.4% of Caucasians (P < .01).
  • After taking into account differences in treatment, comorbidity, and socioeconomic status, there was no statistically significant difference in the risk of all-cause (hazard ratio, 0.97; 95% confidence interval, 0.88-1.08) and disease-specific mortality (hazard ratio, 1.07; 95% confidence interval, 0.92-1.25) between African Americans and Caucasians.
  • No significant differences in the risk of mortality were observed between African Americans and Caucasians after controlling for factors such as treatment and socioeconomic status.
  • [MeSH-major] Lymphoma, Non-Hodgkin / ethnology. Lymphoma, Non-Hodgkin / mortality
  • [MeSH-minor] African Americans. Aged. Aged, 80 and over. Cohort Studies. Comorbidity. Ethnic Groups. European Continental Ancestry Group. Female. Health Status Disparities. Humans. Male. Retrospective Studies. SEER Program. Social Class. Survival Rate

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 American Cancer Society
  • (PMID = 18937267.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / AHRQ HHS / HS / R01-HS016743
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


98. Baker PS, Gold KG, Lane KA, Bilyk JR, Katowitz JA: Orbital burkitt lymphoma in immunocompetent patients: a report of 3 cases and a review of the literature. Ophthal Plast Reconstr Surg; 2009 Nov-Dec;25(6):464-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Orbital burkitt lymphoma in immunocompetent patients: a report of 3 cases and a review of the literature.
  • PURPOSE: To describe a series of 3 immunocompetent patients with the sporadic form of orbital Burkitt lymphoma and review the outcomes of such patients reported in the scientific literature.
  • Cases of orbital Burkitt lymphoma in immunocompromised and African patients were excluded from the review.
  • RESULTS: Current cases and review of the scientific literature resulted in 16 immunocompetent patients with sporadic orbital Burkitt lymphoma.
  • CONCLUSIONS: Sporadic orbital Burkitt lymphoma occurs in immunocompetent individuals with a wide age range.
  • The large number of patients with central nervous system involvement in our review of the literature supports the role of lumbar puncture and neuroimaging in the workup of all patients with orbital Burkitt lymphoma.
  • [MeSH-major] Burkitt Lymphoma / complications. Immunocompromised Host. Orbital Neoplasms / complications. Paranasal Sinus Neoplasms / complications

  • Genetic Alliance. consumer health - Orbital lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19935250.001).
  • [ISSN] 1537-2677
  • [Journal-full-title] Ophthalmic plastic and reconstructive surgery
  • [ISO-abbreviation] Ophthal Plast Reconstr Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 41
  •  go-up   go-down


99. Sissolak G, Abayomi EA, Jacobs P: AIDS defining lymphomas in the era of highly active antiretroviral therapy (HAART): an African perspective. Transfus Apher Sci; 2007 Aug;37(1):63-70
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS defining lymphomas in the era of highly active antiretroviral therapy (HAART): an African perspective.
  • The intermediate to high grade B-cell non-Hodgkin lymphomas are now one of three malignant AIDS defining conditions.
  • While co-infection with oncogenic agents including the human herpes 8 or Epstein-Barr virus offer targets in preventive treatment strategies for these AIDS defining lymphomas (ADL), administration of highly active antiretroviral therapy leading to immune reconstitution permits use of standard or even high-dose cytotoxic drug regimens with curative intent.
  • Socio-economic considerations have an impact especially in resource limited settings while availability of tools for appropriate geno-phenotypic diagnosis and immunological monitoring such as the CD4 cell count will play an important role in the risk stratification as well as disease management.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Acquired Immunodeficiency Syndrome / therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antiretroviral Therapy, Highly Active. Hematopoietic Stem Cell Transplantation. Lymphoma, B-Cell / complications


100. Ozgönenel B, Savaşan S, Rabah R, Mohamed AN, Cushing B: Pediatric EBV-positive T-cell/histiocyte-rich large B-cell lymphoma with clonal cells in the bone marrow without overt involvement. Leuk Lymphoma; 2005 Mar;46(3):465-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pediatric EBV-positive T-cell/histiocyte-rich large B-cell lymphoma with clonal cells in the bone marrow without overt involvement.
  • T-cell/histiocyte-rich large B-cell lymphoma (TCHRLBCL) is a variant of large B-cell lymphoma only rarely encountered in children.
  • Here we report the case of an 8-year-old African American boy with Epstein-Barr virus (EBV)-positive TCHRLBCL who initially presented with right submandibular, anterior cervical and supraclavicular lymphadenopathy.
  • The patient remains in remission 26 months after the initial diagnosis.
  • [MeSH-major] Bone Marrow / pathology. Clone Cells / pathology. Epstein-Barr Virus Infections / pathology. Histiocytes / pathology. Lymphoma, B-Cell / pathology. T-Lymphocytes / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15621841.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down






Advertisement